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Amino Acids
A Ala Alanine
C Cys Cysteine
D Asp Aspartic Acid
E Glu Glutamic Acid
F Phe Phenylalanine
G Gly Glycine
H His Histidine
I lie Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N Asn Asparagine
P Pro Proline
pQ Glp Pyroglutamate
Q Gin Glutamine
R Arg Arginine
S Ser Serine
T Thr Threonine
V Val Valine
W Trp Tryptophan
y Tyr Tyrosine
-V-
Onits of Measure
g grammes
Mg microgrammes
ml millilitres
jjI microlitres
mm millimetres
Mm micrometres
nm nanometres
M molar
mM millimolar
mM micromolar
nM nanomolar
nmoles nanomoles
pmoles picomoles
M XL megaohms
ms milliseconds
mV millivolts
Abbreviation used in some figures
a amide
“VI-
other Abbreviations
ACh acetylcholine
4-AP 4-aminopyridine
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cAMP cyclic adenosine monophosphate
cGMP cyclic guanosine monophosphate
EDTA ethylenediaminetetraacetic acid
EGTA ethylene glycol-bis(oxy-ethylene-niti lo) tetraacetic acid
FITC fluorescein isothiocyanate
5-HT 5-hydroxytryptamine
HPLC high performance liquidchromatography
IBMX isobutylmethylxanthine
RIA radioimmunoassay
s.e.m. standard error of the mean
tetraethylammoniumTEA
ÜV ultraviolet
SUMMARY
1. All seven FMRFamide peptides endogenous to Helix 
stimulate perfused cardiac ventricles isolated from aestivating 
Helix. The five heptapeptide amides (pQDPFLRFamide, NDPFLRFamide, 
NDPYLRFamide, SDPFLRFamide and SEPYLRFamide) are equipotent with 
each other, but more potent than the two tetrapeptide amides 
(FMRFamide and FLRFamide).
2. The two endogenous nonapeptide amide SCPs (small cardioactive 
peptides: SGYLAFPRMamide and MNYLAFPRMamide) are also cardioactive 
in Helix. They are more potent than the heptapeptides. All nine 
peptides increase the beat amplitude or beat strength rather than 
affecting the beat frequency.
3. The potency ratio between the activities of FLRFamide and 
FMRFamide on ventricles from aestivating Helix is significantly 
different (p=0 .0 0 1 ) from that of this peptide pair on ventricles 
from active animals.
4. RIA analysis of extracts fractionated by HPLC indicate that 
all nine peptides are present in the circumoesophageal ganglia 
(brain), the combined visceral and anal nerve trunks, and the 
anterior aorta.
5. Similar analysis of the heart shows that the tetrapeptides 
and SCPs are present in the heart; the heptapeptides are absent.
-viii-
6 . Immunohistochemistry reveals a diffuse FMRFamidergic 
innervation spread evenly throughout the heart. Two clusters of 
neurones (one each in the left and right parietal ganglia) of the 
brain also stain positively with FMRFamide antiserum.
7. Calcium-dependent release of the FMRFamide peptides from the 
brain and the heart has been demonstrated.
8 . The perfused cardiac ventricle isolated from Eledone cirrosa 
is stimulated by the FMRFamide analogues in the reverse order to 
that of the Helix ventricle; FMRFamide is the most potent, 
FLRFamide is slightly less potent, and the heptapeptides are the 
least potent. Six unidentified FMRFamide-immunoreactive peaks 
are present in the nervous tissue (brain, optic lobes and vena 
cava); two of these peaks are probably FMRFamide and FLRFamide.
9. The tetrapeptides (but not heptapeptides) reversibly reduce 
a calcium conductance in the Cl neurone of Helix; this current 
may be required for transmitter release. This effect may explain 
presynaptic inhibition by FMRFamide (cf. Haydon & Man-Son-Hing, 
1988; Haydon & Zoran, 1989).
IX-
CHAPTER ONE
ACTIONS AND DISTRIBUTIONS OF ENDOGENOUS CARDIOACTIVE PEPTIDES IN Helix aspersa
Introduction 
Cardioregulation in Molluscs
Molluscan cardioregu1ation has been a source of interest to 
biologists for at least 100 years. The first experiments were 
concerned with the effects of electrical current applied to an 
isolated heart, such as that of the snail (Foster & Dew-Smith, 
1875), but interest soon extended to the actions of chemical 
agents on the hearts of snails and other molluscs (Ransom, 1884).
Molluscan hearts as bioassays. Some molluscan hearts 
are very sensitive to particular drugs and can therefore be used 
as bioassays, providing a means of both identification and quanti­
tative estimation of these drugs. For example, the isolated 
ventricle of the clam Mercenaria (formerly Venus) mercenaria has 
been used to quantify the acetylcholine (ACh) content of rat 
brain extracts (Welsh & Hyde, 1944) and to bioassay the 
5-hydroxytryptamine (5-HT) content of the mammalian (rat, rabbit 
and dog) brain (Twarog & Page, 1953). Likewise, the isolated 
hearts of Helix and those of species of Octopus and Eledone have 
been employed as bioassays for 5-HT (Erspamer & Ghiretti, 1951). 
Molluscan cardioregulators
Acetylcholine. 5-hydroxytr.vptaroine and dopamine. The 
first three transmitters to be identified as endogenous cardio- 
regulators in molluscs were ACh, 5-HT and dopamine. A summary 
review of these findings has been written by Welsh (1971).
Prosser (1940) suggested that ACh might be an endogenous cardiac 
inhibitor in Mercenaria. as stimulation of the visceral ganglion 
caused inhibition in diastole resembling the effect of synthetic
ACh. Welsh (1954) used paper chromatography and bioassay to 
identify and compare the ACh and 5-HT content of Mercenaria 
mercenaria and Busycon central ganglia. The ratio of the two 
transmitters was 1:4 in Mercenaria and 1:1 in Busycon. Sweeney 
(1963) provided fluorometric and paper chromatographic evidence 
for the presence of dopamine in the ganglia of several molluscan 
species, and the Tapes watlingi heart is excited (increased beat 
amplitude and frequency) by low (10"?M) doses of dopamine and 
inhibited by higher doses (Chong & Phillis, 1965).
Likewise, Kerkut and Cottrell (1963) quantified the ACh and 
5-HT content of Helix aspersa brains with chromatography and 
Helix hearts for bioassay. Their levels were l-5pg and 0.5-4.0pg 
respectively per gramme wet weight of tissue. Dopamine is 
present in the circumoesophageal ring of H. aspersa at 5.5pg/g 
tissue (Kerkut, Sedden & Walker, 1966) and it increases the 
beat amplitude of the isolated H. pomatia heart (Osborne, 1970).
Peptides. ACh, 5-HT and dopamine could not account 
for all the endogenous cardioactive substances in molluscs.
Kerkut and Laverack (1958) reported that a fraction of an extract 
of Helix aspersa brain stimulated the isolated Helix heart. 
Moreover this extract and 5-HT were pharmacologically and 
chemically distinguishable (Kerkut & Laverack, 1960). Jaeger 
(1961, 1966) also detected a cardioactive substance in the snail 
Strophocheilus oblongus. that was neither 5-HT nor ACh; he 
suggested it might be a peptide. Frontali, Williams and Welsh 
(1967) prepared extracts from Busycon canaliculatum and 
Mercenaria mercenaria and fractionated them on a Sephadex G-15 
column. Using the isolated M. mercenaria heart for bioassay, six
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peaks of cardioactivity were detected: two inhibitory peaks (ACh 
and dopamine) and four unidentified excitatory peaks (A, B, C and 
D according to the order of their elution from the column). When 
the fractionated extracts of M. mercenaria ganglia, M. mercenaria 
heart and haemolymph, and Busycon ganglia were assayed and 
compared, only peak C was common to all tissues. Furthermore, C 
also seemed the most potent of the four excitatory peaks, so 
attention was focused upon it. Frontali, Williams and Welsh 
(1967) suggested that peak C was peptidic in nature.
In 1977, Price and Greenberg purified sufficient quantities 
of peak C from the clam Macrocallista nimbosa to determine its 
chemical identity. The central ganglia were dissected from 
several thousand clams. The active substance was extracted and 
purified by column centrifugation with a Sephadex G-15 and 
CM-Sephadex. Electrophoresis, thin layer chromatography and 
various chemical tests were used to characterise the fractionated 
extract and the composition of the major component was determined 
with an automatic amino acid analyser. Controlled enzymic 
digestion (Edman method) combined with dansylation revealed the 
sequence Phe-Met-Arg-Phe-NHg (FMRFamide).
FMRFamide
FMRF amide-conta in ing species. If peak C generated interest 
and encouraged research while its active components were still 
unidentified, the elucidation of the structure and subsequent 
commercial availability of FMRFamide has been like a spark 
setting a forest alight. FMRFamide itself has been positively 
identified in several classes of Mollusca: (1) Polyplacophora:
granulata (Price, Davies, Doble & Greenberg, 1987),
(2) Gastropoda: subclass (a) Prosobranchia: Busycon contrarium, 
Pomacea naludosa (Price, 1986), (b) Opistobranchia: Aplysia
brasiliana (Lehman, Price & Greenberg, 1984), (c) Pulmonata:
Order (i) Basommatophora: Helisoma. (Price, Davies, Doble & 
Greenberg, 1987), Lvmnaea stagnalis (Ebberink & Joosse, 1985), 
Siphonaria pectinata (Price, Cobb, Doble, Kline & Greenberg,
1987), Stagnicola palustris (Price, 1986), (ii) Stylommatophora: 
Limax maximus (Krajniak, Greenberg, Doble & Price, 1985),
Succinea campestris. Cepaea nemoralis (Price, 1986),
Strophocheilus oblongus (Price, Davies, Doble & Greenberg, 1987),
(3) Cephalopoda: Octopus vulgaris (Voigt & Martin, 1986) and 
Octopus bimaculoides (Price, 1987) (4) Bivalvia: Geukensia 
demis, sa, (Price, 1986) and, of course. Macrocall ista nimbosa from 
which it was originally sequenced (Price & Greenberg, 1977a).
This list is not exhaustive, although it suggests that FMRFamide 
is ubiquitous in molluscs. Moreover, FMRFamide is not the only 
peptide responsible for the cardioactivity of peak C.
FMRFamide analogues in Helix aspersa. To date, seven 
analogues of FMRFamide have been identified in Helix alone: one 
other tetrapeptide amide (Phe-Leu-Arg-Phe-NH2 [FLRFamide]) and 
five heptapeptide amides. The sequences of these peptides are 
listed in table 1 .
Phe-Met-Arg-Phe-NH2 (FMRFamide)Phe-Leu-Arg-Phe-NH2 (FLRFamide)Glp--Asp-Pro-Phe-Leu-Arg-Phe-NH2 (pQDPFLRFamide)Ser--Asp-Pro-Phe-Leu~Arg-Phe-NH2 (SDPFLRFamide)Asn--Asp-Pro“Phe-Leu-Arg-Phe-NH2 (NDPFLRFamide)Asn--Asp-Pro-Tyr-Leu-Arg-Phe-NH2 (NDPYLRFamide)Ser--Glu-Pro-Tyr-Leu~Arg-Phe-NH2 (SEPYLRFamide)
Table 1. The FMRFamide-related peptides of Helix aspersa.
The initial analysis of Helix brain extracts revealed cardio­
activity that was not due to FMRFamide. In fact, there was 
great doubt that FMRFamide itself was present in Helix ganglia. 
With perseverance, however, not only FMRFamide, but also the 
heptapeptide analogue pQDPFLRFamide, were identified (Price, 
Cottrell, Doble, Greenberg, Jorenby, Lehman & Riehm, 1985; Price, 
Davies, Doble & Greenberg, 1987). FLRFamide and SDPFLRFamide 
were the next analogues to be sequenced from Helix (Price, Doble, 
Lee & Greenberg, 1987). The sequencing of NDPFLRFamide (Price, 
Lesser, Lee, Doble & Greenberg, in prep.) seemed to signal the 
end of the list of analogues in Helix. Indeed it might well have 
been, but curiosity and the development and use of a second 
antiserum (Q2) raised, not against YGGFMRFamide, but against 
conjugates of pQDPFLRFamide and DDPFLRFamide, revealed two 
further analogues: NDPYLRFamide and SEPYLRFamide (Price, Lesser, 
Lee, Doble & Greenberg, in prep.). Unlike the previous three 
heptapeptide amides to be sequenced from Helix, these latter two 
have a tyrosine substituted for one of the phenylalanine residues 
(Phe^); i.e., an hydroxyl group has been added to the phenyl
ring. This seemingly insignificant substitution reduces the 
affinity of the peptides for the original antiserum (S253) 
sufficiently that they bind very poorly to S253, and so compete 
very poorly with the trace (pQYPFLRFamide) in the radioimmuno­
assay used by Price and his co-workers. Thus the introduction of 
the Q2 antiserum was absolutely critical to the detection and 
purification of the last two peptides. The list may still be 
incomplete.
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Interest in FMRFamide has generally been confined to its 
actions on molluscan muscle or neurones, its effects on the 
mammalian circulation and central nervous system, and its 
distribution (determined by immunoreactivity) in the animal 
kingdom. This latter effort has led to the discovery and 
identification of still further peptides.
Effects of FMRFamide on molluscan hearts. The myocardial 
effects of FMRFamide have been well investigated in bivalves, and 
these actions can be excitatory, inhibitory, or both (depending 
on the dose) and similar or dissimilar to those of 5-HT 
(depending on the species) (Painter & Greenberg, 1982).
FMRFamide is a cardioexcitor in Rapana in which it seems to 
adjust the beat frequency to an approximately constant value 
(Kobayashi, 1987). FMRFamide increases the cardiac output of 
Busycon canaliculatum solely by increasing the heart rate as no 
increase in stroke volume is apparent; but higher doses (10~?M), 
decrease both the stroke volume and heart rate (Smith & Hill, 
1987). When pQDPFLRFamide and FMRFamide were compared on the 
isolated heart of Helix aspersa. pQDPFLRFamide was approximately 
one hundred times more potent than FMRFamide (Price, Cottrell, 
Doble, Greenberg, Jorenby, Lehman & Riehm, 1985).
Effects of FMRFamide on the leech heart. FMRFamide, or 
a similar molecule, seems to have a cardioregu1atory role in the 
leech Hirudo medicinalis (Kuhlman, Li & Calabrese, 1985a,b; Li & 
Calabrese, 1987). Immunoreactivity to FMRFamide antisera has 
been observed in three types of neurones involved in cardio- 
regulation: motor neurones, modulatory neurones and interneurones 
which synapse onto the heartbeat central pattern generator
6 —
neurones. Application of FMRFamide to the heart or central 
pattern generator mimics the actions of the innervating neurones. 
Individual cells that stained positively with the FMRFamide 
antisera and that innervate the heart have been removed from the 
leech and their contents analysed by HPLC and subsequent RIA.
The results, though inconclusive, suggest strongly that they 
contain FMRFamide itself. This conclusion is lent credence by 
the finding of authentic FMRFamide in the polychaete annelid.
Nereis virens by Krajniak and Price (1989). Thus, FMRFamide is 
probably an endogenous cardioregulator in the leech.
Effects of FMRFamide on non-cardiac muscles. Other 
molluscan muscles respond to FMRFamide. One of these, the 
Busycon radula protractor muscle, was the primary bioassay used 
in the identification of FMRFamide (Price & Greenberg, 1977a). 
FMRFamide induces a slowly developing, but sustained contracture 
in this muscle; the effect decays slowly in the continued 
presence of the agonist, but disappears rapidly upon washing 
(Price & Greenberg, 1980).
At concentrations of 10"?M and greater, FMRFamide induces 
catch-contractures in the anterior byssus retractor muscle of 
Mvtilus edulis and Geukensia demissa (Painter, 1982); 
characteristically, the muscles relax only slowly after washing, 
but rapidly after bath application of 5-HT (Greenberg, Painter & 
Price, 1981). ACh-induced catch contractures are relaxed by lower 
( 10"®-10~'^M) concentrations of FMRFamide (Muneoka & Matsuura, 1985)
Electrically-induced twitch contractions of the Rapana 
thomasiana radula protractor muscle are potentiated by FMRFamide, 
though the retractor muscle is unaffected (Yanagawa, Fujiwara,
Takabatake, Muneoka & Kobayashi, 1988). Conversely, FLRFamide 
potentiates electrically-induced twitch contractions of the 
retractor muscle, but is without effect on the protractor muscle. 
In this particular instance, FMRFamide and FLRFamide are similar 
in their effects, but by acting on antagonistic muscles they are 
opposing each other. Thus, different components of a single 
function (radular movement) are allocated to different members of 
the same peptide family. This is an unusual example of the two 
tetrapeptides appearing to act at two distinct receptors.
FMRFamide inhibits spontaneous and ACh-induced contractions 
of the Aplysia californica anterior gizzard, but has no effect on 
the adenylate cyclase activity of this organ (Austin, Weiss & 
Lukowiak, 1983).
Effects of FMRFamide analogues on molluscan neurones.
The actions and possible mechanisms of action of FMRFamide and 
some analogues have been compared on identified Helix neurones 
(Boyd & Walker, 1987; Cottrell & Davies, 1987). These will be 
discussed in Chapter Three.
Effects of FMRFamide in mammals. In mammals, intracerebro- 
ventricular injection of FMRFamide causes an increase in blood 
pressure on its own and partially blocks [D-Ala^,Leu^]enkephalin- 
induced hypotension (Chai, Tang & Han, 1986). When applied 
topically, however,it has a vasodilatory effect in the 
microcirculation (Koo, Chan, Ng & Greenberg, 1983). Antinoci­
ceptive actions of morphine are also attenuated by FMRFamide 
(Tang, Yang & Costa, 1984), as is morphine-induced feeding 
(Kavaliers, Hirst & Mathers, 1985). These results suggested that 
many mammalian actions of FMRFamide may be opioid-related.
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Immunohistochemistry and the discovery of related peptides. 
Immunohistochemistry with antisera raised against FMRFamide and 
its analogues has been a fruitful pursuit. Positive staining has 
been observed in a range of animals and the references are 
numerous. One representative survey was conducted by Boer, Schot, 
Veenstra and Reiohelt (1980) in which staining was noted in the 
central nervous systems of a snail (Lvmnaea stagnalis). various 
insects (Leptinotarsa decemlineata. Periplaneta americana.
Locusta migratoria and Pieris brassicae). the black molly (a 
fish) (Poecilia latipinna) and a mouse. Thus FMRFamide or (more 
probably) similar peptides are widely distributed throughout the 
animal kingdom. On its own, however, immunohistochemistry 
provides little information, only hinting at what might be 
present. The staining observed must be supported by additional 
information; the antigens responsible must be identified.
Some workers have identified the source of the observed 
immunoreactivity with the result that several new peptides have 
been discovered. For example, LPLRFamide from the chicken has 
effects on the central nervous system and blood pressure of the 
rat that mimic those of FMRFamide (Dockray, Reeve, Shively,
Gayton & Barnard, 1983). An octapeptide (FLFQPQRFamide,
F-8 -F-NH2 ) and an octadecapeptide {AGEGLSSPFWSLAAPQRFamide, 
F-I8 -F-NH2 ) have also been sequenced from bovine brain (Yang, 
Fratta, Majane & Costa, 1985). When injected intracerebro- 
ventricularly, the bovine peptides decrease the tai1-flick 
latency in rats, the octapeptide being more potent.
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Two octapeptides (Ser-Asp-Arg-Asn-Phe-Leu-Arg-Phe-amide and 
Thr-Asn-Arg-Asn-Phe-Leu-Arg-Phe-araide) have been sequenced from 
the pericardial organs of Homarus (Trimmer, Kobierski & Kravitz, a
1987); their roles remain to be elucidated. The decapeptide 
SchistoFLRF-amide (Pro-Asp-Val-Asp-His-Val-Phe-Leu-Arg-Phe-amide) 
has been sequenced from Schistocerca gregaria (Robb, Packman &
Evans, 1989) and is a potent cardioinhibitory agent on the 
semi-isolated heart of the locust and potentiates contractions of 
the extensor-tibiae muscle at low concentrations while producing 
a variable biphasic response at higher concentrations.
AFl (Lys-Asn-Glu-Phe-Ile-Arg-Phe-amide) from the nematode <
Ascaris suum (Cowden, Stretton & Davis, 1989) inhibits locomotory ;
movements of intact Ascaris, blocks slow oscillatory potentials 
and reduces the input resistance of inhibitory neurones at the 
cellular level.
A family of coelenterate peptides is being revealed with the 
aid of antisera raised against RFamide, though the initial 
findings were generated with FMRFamide antisera (Grimmelikhuijzen, 
Dockray & Schot, 1982), This peptide family includes Antho-RFamide 1 
(<Glu-Gly~Arg-Phe-NH2 )J (Grimmelikhuijzen & Graff, 1986), 
Antho-RWamide I (<Glu-Ser-Leu-Arg-Trp-NH2 ) and Antho-RWamide II 
(<Glu-Gly~Leu-Arg-Trp-NH2 ) (Graff & Grimmelikhuijzen, 1988a,b) 1
and Pol-RFamide (<Glu-Leu-Leu-Gly-Gly~Arg-Phe-NH2 ) (Grimmelikhuijzeh 
Hahn, Rinehart & Spencer, 1988). Generally, these peptides seem 
confined to neural elements (according to immunohistochemical s
evidence), and they may act as neurotransmitters or, neuro- ^
modulators of slow muscles in coelenterates (McFarlane, Graff & 
Grimmelikhuijzen, 1987).
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SCPs
Their partial purification from Helix. Almost 
simultaneously with the elucidation of the structure of FMRFamide, 
Lloyd (1978a,b) was investigating four peaks of cardiac activity 
from Helix aspersa: an inhibitory peak 2 (assumed to be ACh), and 
three excitatory ones. Peak 4 appeared to be 5-HT, but peaks 1 
and 3 were not due to any of the then known cardioactive 
substances. The activities of peaks 1 and 3 were destroyed by 
proteolytic enzymes suggesting that they were due to peptides. 
Peak 1 could be extracted from the haemolymph, atrium and sub- 
oesophageal ganglia, but not the cerebral ganglia or ventricle.
Gel filtration suggested a molecular weight in excess of 1500 
daltons, so the active component was named large cardioactive 
peptide (LCP). The distribution of peak 3 was more restricted 
(being confined almost completely to the nervous system), and its 
activity was stable to heat, acid and alkaline treatment. As its 
apparent molecular weight was less than 800 daltons, it was named 
small cardioactive peptide (SOP).
The presence of LCP in the haemolymph at levels sufficient 
to excite the heart suggested a neurohormonal role, perhaps even 
including cardioregulation. Despite the ability of SCP to 
stimulate the isolated heart, the apparent restriction of its 
distribution to nervous tissue led Lloyd to doubt that it had any 
physiological role to play in cardioregulation.
The change to Aplysia. Possibly despairing of Helix 
(other than using its heart for bioassay), Lloyd (1982) turned 
his attentions to Aplysia. Like Helix. Aplysia also contained 
non-classical cardioactive substances. The peak equivalent to
11 -
LCP was missing, but the SCPs (now two distinct peaks) were 
present. However, their identity with the SCP fractions of Helix 
has never been demonstrated.
Structures of SCP^ and SCPg and their cardiac effects 
in Aplysia. Sufficient quantities of the SCPs were finally 
extracted from Anlvsia for their structures to be determined.
SCPg was first extracted from the central nervous system of A. 
brasiliana: and has the sequence Met-Asn-Tyr-Leu-Ala-Phe-Pro- 
Arg-Met-NHg (MNYLAFPRMamide) (Morris, Panico, Karplus, Lloyd 
& Riniker, 1982). The gene encoding the precursor molecule in 
Aplysia californica was sequenced next (Mahon, Lloyd, Weiss, 
Kupfermann & Scheller, 1985). The precursor protein contained 
one copy of SCPg: an adjacent sequence was assumed to be SCP^. 
Only one copy of each was present. Lastly, SCP^ (Ala-Arg-Pro-Gly- 
Tyr-Leu-Ala-Phe-Pro-Arg-Met-NHg (ARPGYLAFPRMamide) was extracted 
from the gut of A. californica. confirming the prediction from 
molecular genetics (Lloyd, Kupfermann & Weiss, 1987). Both 
peptides are equipotent and appear to act through the mediation 
of cAMP (Lloyd, Kupfermann & Weiss, 1985) on the isolated Aplysia 
heart (Cawthorpe, Rosenberg, Colmers, Lukowiak & Drummond, 1985).
Distribution of SCPs in several molluscan species. 
Biochemical and immunohistochemical studies in Aplysia indicate 
that the SCPs are found throughout the nervous system, 
particularly the buccal ganglia where the concentration is 
ten-fold greater than in other ganglia; they are present in 
equimolar ratios (Lloyd, Mahon, Kupfermann, Cohen, Scheller & 
Weiss, 1985) .
12 -
SCP-immunoreactivity has also been noted in the central 
nervous system (including a buccal neurone with an axon in the 
gastro-oesophageal connective) in several other opistobranchs 
(Longley & Longley, 1985). Bll and B12 (two large buccal 
neurones in the nudibranoh Tritonia) contain SCP in sufficient 
quantity for extraction and bioassay (on the Helix heart) (Lloyd, 
1982) and identification as SCPg (Willows & Lloyd, 1983). Not 
surprisingly, the Tritonia gut also responds to SCP (Lloyd, 1982).
SCPs and feeding. The association of the SCPs with feeding 
behaviour has been a basis of much research, overriding the 
dwindling interest in a possible cardiovascular role. SCP^ was 
even sequenced from Anlvsia gut extracts (Lloyd, Kupfermann & 
Weiss, 1987)! Interest has so far been confined to several 
molluscs: Helisoma trivolvis (Murphy, Lukowiak & Stell, 1985), 
Tritonia diomedea (Lloyd & Willows, 1988; Willows, Lloyd & 
Masinovsky, 1988), Limax maximus (Prior & Watson, 1988), not to 
mention Anlysia (Lloyd, Kupfermann & Weiss, 1984).
Bath application of SCPg stimulates the patterned motor 
activity of neurones B5 and B19 in isolated buccal ganglia 
preparations of Helisoma. B5 innervates the gut and B19; B19 
innervates a supralateral radular tensor muscle. Although B5 and 
B19 do not appear to stain with SCPg antiserum, other neurones 
in the buccal ganglia do, and one or more of them may synapse 
onto B5 or B19.
In Tritonia two SCPg-containing neurones (Bll and B12) 
appear to synapse (though perhaps not directly) onto a third 
neurone, B5, intracellular stimulation of which elicits 
contractions of the buccal mass inducing swallowing. Electrical
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stimulation of Bll enhances the activity of B5 and, itself, 
induces a backwardly-directed peristalsis of the foregut 
compatible with swallowing. Stimulation of B12 inhibits the 
output of B5 and induces a forwardly-directed contraction of the 
foregut, which would push food toward the mouth and so is not 
compatible with swallowing. Superfusion of the isolated gut 
with SCPg enhances peristalsis in like manner to stimulation 
of Bll. Thus it is quite possible that Bll releases SCPg onto 
the anterior gut which responds with peristaltic movements.
SCPg can initiate or lower the threshold for initiation 
of the feeding motor program of Limax. However SCPg has no 
effect on this program once it has been initiated. SCPg also 
increases the burst frequency of the fast salivary burster 
neurone when bath applied to the isolated central nervous system. 
Many buccal neurones are immunoreactive to SCPg antiserum.
SCPg is present in the buccal ganglia and the nerve that 
innervates the accessory radula closer muscle of Aplysia. At 
nanomolar concentrations SCPg potentiates contractions of 
this muscle elicited by nervous or chemical stimulation. The 
potentiation appears to be mediated via cAMP as SCPg increases 
the levels of cAMP in this muscle.
Thus, SCPg appears to initiate or enhance muscular activity 
associated with feeding in several molluscan species. Moreover, 
these species also display SCPg immunoreactivity in their buccal 
ganglia and its associated musculature. Therefore, SCPg probably 
plays an important modulatory role in feeding in molluscs.
14
Ultrastruotural localization, transport and release of 
SCPs. Immunoelectron microscopy of Aplysia central ganglia 
showed the SCP immunoreactivity was confined to dense-core 
vesicles (Cropper, Lloyd, Reed, Tenenbaum, Kupfermann & Weiss, 
1987). Transport (Lloyd, 1987) and release (Lloyd, Schacher, 
Kupfermann & Weiss, 1986) of the peptides has also been 
demonstrated in Aplysia.
Co-localization of SCPs with other transmitters. The 
SCPs can be present in cells with other transmitters such as ACh 
(Lloyd, Mahon, Kupfermann, Cohen, Scheller & Weiss, 1985) and 
FMRFamide (Lloyd, Frankfurt, Kupfermann & Weiss, 1985).
Post- and pre-synaptic facilitation. The SCPs can mediate 
both postsynaptic (Lloyd, Kupfermann and Weiss, 1984) and 
presynaptic (Abrams, Castellucci, Camardo, Kandel & Lloyd, 1984) 
facilitation. The former process involves raising cAMP levels 
within the accessory radula closure muscle of Aplysia. thereby 
potentiating contractions; this effect is similar to that of
5-HT. Presynaptic facilitation by SCPs is also 5-HT-like; it 
involves a cAMP-dependent closure of a 5-HT-sensitive potassium 
channel, thereby broadening the presynaptic action potential and 
facilitating transmitter release.
SCPs of Helix. At long last. Price (1987) returned to 
the neglected Helix aspersa armed with a rabbit polyclonal 
antibody against SCPg from H. Morris (Imperial College, London). 
After several attempts he was able to extract and purify 
sufficient peptide for amino acid analysis. On speculation more 
than hard evidence, he hypothesised the possible sequence: 
Ser-Gly-Tyr-Leu-Ala-Phe-Pro-Arg-Met-NH2 (SGYLAFPRMamide). This
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sequence has since been confirmed, as has the presence of SCPg 
(MNYLAFPRMamide) in Helix (Price, Lesser, Lee, Doble and 
Greenberg, in prep).
With this information at hand, we now turn to the actions 
and distributions of these peptides (listed in Table 2) in the 
common garden snail, Helix aspersa.
FMSFamide-related peptides
Phe-Met-Arg-Phe-NH2 (FMRFamide)
Phe-Leu-Arg-Phe-NH2 (FLRFamide)Glp“Asp“Pro-Phe-Leu“Arg-Phe~NH2 (pQDPFLRFamide)Ser-Asp-Pro-Phe-Leu-Arg-Phe~NH2 (SDPFLRFamide)Asn-Asp-Pro-Phe-Leu~Arg-Phe-NH2 (NDPFLRFamide)Asn-Asp-Pro-Tyr-Leu-Arg-Phe-NH2 (NDPYLRFamide)Ser-Glu-Pro-Tyr-Leu-Arg-Phe-NH2 (SEPYLRFamide)
SCPs
Met-Asn-Tyr~Leu-Ala-Phe~Pro“Arg-Met-NH2 (MNYLAFPRMamide)
Ser-Gly~Tyr-Leu-Ala~Phe-Pro-Arg-Met-NH2 (SGYLAFPRMamide)
Table 2. The endogenous cardioactive peptides of Helix aspersa.
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Methods and Materials 
An Explanation of the Principles Underlying HPLC and RIA
Fractionation of the extracts by HPLC. In the studies 
reported here, HPLC (High Performance Liquid Chromatography) was 
used to separate the peptides extracted en mass from the various 
tissues; to then identify these peptides, one of three antisera 
(to FMRFamide or SCPg) was used in the appropriate RIA 
(RadiolmmunoAssay).
The peptides were extracted from the tissues in acetone and 
the extract loaded onto an HPLC column. According to the 
solvents and gradients employed, the individual peptides will be 
retained on the column for varying lengths of time and will thus 
elute in sequence. The order of elution and the approximate 
elution time for each peptide can be determined by loading 
standards (i.e. known quantities of known peptides) on to the 
column, and running the same gradient after all the extracts or 
samples have been run. Although the order of elution remains 
constant as does the approximate time of elution of each peptide, 
the detection times for the standards do not necessarily 
correspond exactly to the elution times of the extracts. In the 
studies reported in this thesis, there were two reasons for the 
differences in the detection times of standards by HPLC and 
extracts by RIA. First, the baseline level of UV absorbance 
established before each run rose and fell markedly when the 
sample was loaded onto the column. Only after the absorbance had 
returned close to the baseline, was the loading judged to be 
complete, and the elution gradient initiated- As this judgement 
was subjective, amd individual samples varied in their UV
- 17
absorptions, the elution gradient could not be started at exactly 
the same time for each run. Secondly, there was a time lag 
(30-60 seconds) between the monitoring of an absorbance change 
and the delivery of the responsible drops of eluate to the 
collecting vials.
The net result of these two factors is that the order of 
elution of the peptides from a particular column run with a 
particular gradient remains constant, but the exact time of 
elution of a particular fraction varies slightly from run to run. 
Therefore, the relative positions of the various peaks of immuno­
reactivity are of greater value in evaluating the occurrence of 
peptides in a sample than their exact elution times.
Detecting the peptides in the fractions by RIA. RIAs 
are based on the ability of an antigen to displace a radioactive 
trace bound to an antibody. The degree of displacement can be 
monitored by counting the radioactivity of either the supernatant, 
or the sediment, depending on the exact protocol employed.
Three polyclonal antisera raised in rabbits were used in the 
RIA. The first two (designated S253 and Q2) were produced by D.
A. Price (Whitney Laboratory, University of Florida). S253 was 
raised against a conjugate of YGGFMRFamide. Q2 was initially 
raised against a conjugate of pQDPFLRFamide, but the rabbit was 
boosted with a conjugate of DDPFLRFamide. The third (SCPg) was 
raised against SCPg and supplied by H. R. Morris (Imperial 
Co11ege, London).
The protocol described here for the extraction and identifi­
cation of the peptides using HPLC combined with RIA was developed 
in the laboratory of D. A. Price; earlier versions have been
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described previously (Price, Cobb, Doble, Kline and Greenberg, 
1987). The HPLC protocol in use here is the simplest in use at 
the Whitney Laboratory.
Methods
Preparation of extracts and analysis by HPLC and RIA.
The desired tissue (heart, brain, nerve trunks or aorta) was 
dissected from Helix aspersa. weighed and immersed in four times 
its mass of acetone, and kept at -20°C overnight. Usually, 
tissue from ten animals was used, but five animals were 
sufficient for the cerebral and suboesophageal ganglia. The 
atrium to the initial millimetre or so of aorta was removed from 
the snail and analysed as heart tissue. The suboesophageal ring 
was removed and analysed as the brain. The nerve trunks were 
dissected free as long as they remained free from other organs 
(so that there was no possibility of contamination by other 
tissue). Thus not all the nerve trunk from a particular animal 
was analysed for its peptide content but rather approximately 
half the nerve tissue was used. Similarly, approximately half 
the length of aorta from the suboesophageal ring was removed as 
the half closer to the heart was more closely connected to other 
tissue. The aortas were flushed with saline before their 
immersion in acetone to remove any blood within them.
After 12-18 hours of incubation, the extract was poured off 
the tissue, which was then rinsed in several more volumes of 
acetone; the extract and rinse were pooled. The acetone was 
evaporated off with an air stream. The remaining liquid was 
diluted with HPLC buffer A (aqueous 0.1% trifluoracetic acid 
(TFA)), and the liquid centrifuged at 1000 times gravity to
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sediment any particles. The supernatant was loaded onto a 
reverse-phase HPLC column (Aquapore RP-300, 220 x 2.1mm, 7pm).
The column was washed with buffer A, the flow switched to 20% 
buffer B (80% acetonitrile with 0.1% TFA), and a gradient started 
to 50% buffer B over 30 minutes. The flow rate was O.Sml/minute 
throughout, and 0.5 minute (0.250ml) fractions were collected. 
Aliquots (2pl or 5pl) were taken from each fraction. RIA buffer 
(lOmM Na2HP04.7H2O, 0.9% NaCl, 25mM EDTA, 0.1% merthiolate,
1% BSA in distilled water, pH 7.5) was added to give a total 
volume of 50pl. Antiserum (lOOpl: Q2 at 1:500; S253 at 1:10,000; 
or SCPg at 1:10,000) and lOOpl trace (^^^I-pQYPFLRFamide with 
Q2 and S253, or ^^^I-SCPg with SCPg) were both diluted in RIA 
buffer, and added to each tube. Standard curves were made from 
twofold serial dilutions of the appropriate peptide: FMRFamide 
was used with S253, FLRFamide with Q2, and SCPg with SCPg.
Thus the contents of the sample tubes could be quantified by 
comparing their levels of radioactivity with those of the tubes 
containing known amounts of the appropriate peptide and antiserum. 
The tubes were then incubated overnight (a minimum of 12 hours) 
at 4*^ C. On the following day, 1ml dextran-coated charcoal 
solution (2.14g Na2HP04.7H2 O, 0.28g NaH2 P0 4 .H2Û,
O.lg merthiolate, 2.5g charcoal, 0.25g dextran per litre water, 
pH 7.6) was added to each tube. After 10 minutes of incubation, 
the tubes were spun at 1000 x gravity for 10 minutes at 20°C.
The supernatant was pipetted or decanted off and counted in a 
gamma counter (LKB Model 1275 Minigamma).
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The distribution of immunoreactivity within the heart and 
nervous system determined by wholemount imrounohistochemistry.
The hearts or circumoesophageal rings (brains) were dissected 
from fresh snails. The tissue was pinned out on a Sylgard base 
in a solution containing paraformaldehyde and picric acid (20g 
paraformaldehyde, 150ml 0.1% picric acid solution in 1 litre 0.IM 
phosphate buffer [2.6g NaH2 P0 4 .Hg0 , 11.5g Na^HPO^ 
in 1 litre distilled water, pH 7.5]). The nerve tissue was 
desheathed almost to the last layer and excess tissue removed 
from around the other organs. The hearts were split open 
longitudinally and repinned. The fixative in which the finer 
dissection had taken place was replaced with clean solution. The 
dissection dish was covered with Parafilm and kept at 4°C 
overnight (a minimum of 12 hours).
On the following day the fixed tissue was washed in 80% 
ethanol (6 solution changes at 10 minute intervals), then 
dehydrated through ethanol (95, 100, 100%) to xylene (50/50 with
ethanol, 100, 100, 100, 50/50) and rehydrated (100, 100, 95, 80,
70, 50% ethanol) to phosphate buffered saline (PBS: lOmM 
Na2HP04.7 H 2O, 0.9% NaCl in distilled water, pH 7.5).
The solutions were changed at 30 minute intervals.
The tissue was then transferred to a blocking solution (10% 
normal goat serum in PBS^ (0.01% merthiolate, 0.25% Triton 
X-100 in PBS), and placed on a shaker in the dark at 4°C for 
up to 12 hours. The tissue was then transferred to the primary 
antibody solution (S253 at 1:200 diluted in blocking solution)
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for 48 hours, washed in PBS'*' for 24 hours (with 15 changes of 
solution), incubated in goat-anti-rabbit antiserum conjugated to 
FITC (diluted 1:50 in blocking solution) for 24 hours, washed for 
24 hours in PBS'*' with 15 changes, and mounted in carbonate-buffered 
glycerol (1 part 0.5M Na^COg/NaHCOg : 2 parts glycerol, pH 8.6).
The mounted tissues were viewed under epifluorescence with a 
Nikon microscope with 460 - 485nm excitation wavelength and 510nm 
cut-off wavelength. Photographs were taken with a Nikon camera 
equipped with a Nikon automatic exposure meter; Ektachrome 400 
ASA film. (Method modified from Lehman and Price (1987).)
Controls for specificity of staining. Some ganglia were 
treated as usual but incubated with primary antiserum which had 
been preincubated with 10“^M FMRFamide for 24 hours. Only 
background fluorescence was observed when these ganglia were 
viewed under epifluorescence.
Calcium-dependent release of the FMRFamide peptides
The heart. The heart was cannulated at the aortic end 
of the ventricle. The aorta was cut distal to the insertion of 
the cannula, and the atrium cut at its junction with the vein.
The cannula was connected to a loop system, devised by K. Paysa 
(1987), but modified as follows. The dead space of the loop was 
reduced to a minimum by connecting the three-way taps directly to 
the Y-tubes - especially at the sample loop, so that a sharp 
front of saline would enter the heart (Fig. 1). The sample loop 
had a volume of 1.8ml. The perfusion rate was set very low 
(2Op1/minute).
The heart was first perfused with a normal saline (7mM 
CaCl2 , 4mM KCl, 5mM MgCl2 , 80mM NaCl, 5mM TrisHCl, pH 7.5)
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Figure 1. The closed loop system for the stimulated release of FMRFamide peptides from the isolated heart (shown) and circumoesophageal ring (not shown) of Helix (modified from Payza, 
1987). When the taps are adjusted to prevent saline flowing across the broken (dashed) lines in the three-way taps, the saline flows through the shunt loop and the desired saline can be injected into the sample loop through the injection cap, displacing the saline already present which flows out the waste tubing. If the taps are then adjusted so that flow across the dotted lines is obstructed, then the contents of the sample loop will flow through the heart. Note the flow through the heart is 
from the ventricle to the atrium. This allowed the atrium, ventricle, and atrial-ventricular junction all to be exposed to the salines and thus to contribute to the release of peptides.
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for 30 minutes to allow the heart to equilibrate with its 
new conditions and to wash away blood and any free enzymes or 
other proteins. Drops of perfusate were then collected in 
sequence, one drop per tube. After five drops had been 
collected, the sample loop was filled with OmM CaCl2/40mM KCl 
saline (the calcium was replaced by magnesium and sodium was 
replaced by potassium to keep the monovalent ion and divalent ion 
totals constant), and twenty to thirty more drops were collected. 
The saline was then returned to its starting composition and a 
further twenty to thirty drops were collected. In normal saline, 
the heart presumably repolarised and the calcium levels were 
restored. Finally, the heart was perfused with 7mM CaCl2/40mM 
KCl saline (i.e., normal calcium, high potassium) and twenty to 
thirty drops collected.
At the end of the experiment, each tube was assayed by RIA, 
each 40pl drop serving as a sample; i.e. lOOpl ^^^I-pQYPFLRFamide 
trace and lOOpl S253 antiserum were added to each tube, and the 
assay carried out as described above.
The oircumoesQphagea1 ring. The artery supplying the 
buccal mass was ligated and the middle foot artery (Pentreath & 
Cottrell, 1970) cannulated. After the remaining vessels and 
nerves had been cut as distal to the circumoesophageal ring as 
possible, the ring was removed and hung from its cannula in a 
manner similar to the heart. The protocol was somewhat different 
to that for the heart. First, the perfusion rate was increased 
to 40pl/minute. Also, the order of the perfusing solutions, 
after the 30 minute equilibration and rinsing period was: 7mM
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CaCl2/4mM KCl; 2mM CaCl2/4mM KCl; 2mM CaCl2/40mM KCl;
7mM CaCl2/4mM KCl; and 7mM CaCl2/40mM KCl. As with the 
heart, twenty to thirty drops were collected for each condition, 
except for the initial saline, where only 5 drops were collected. 
The tubes were assayed by RIA, as for the heart.
Several points became apparent as this protocol was 
developed. The total monovalent and divalent ion concentrations 
had to remain constant. Altering them, especially the divalent 
ion total, affected the sensitivity of the RIA. A similar 
observation was made by Carroll, Carrow and Calabrese (1986).
The use of TrisHCl as the saline buffer helped to restore some of 
the sensitivity lost through using the divalent ions. Due to the 
altered sensitivity of the assay the standard curve was also made 
in saline rather than RIA buffer; i.e., RIA buffer was still used 
to dilute the antiserum and trace, but the sample volume of each 
tube consisted of 40pl Tris-buffered saline rather than RIA 
buffer. Finally, the values for the histograms were subjected to 
a running average of three to help reduce the effect of stray 
drops, and to clarify the overall pattern of release.
A comparison of the effects of the peptides on the isolated 
ventricle. The method of Payza (1987) was used to bioassay the 
peptides on ventricles isolated from aestivating Helix. In one 
case, the potencies of FLRFamide and FMRFamide were compared on 
ventricles from active animals. The taps were positioned as for 
the release experiments (Fig. 1). Each ventricle was perfused at 
a minimum rate of BOOpl per minute (the rate varied between 
ventricles, but was constant for a given ventricle) with saline 
(80mM NaCl, 5mM KCl, 6mM MgCl2 , YmMCaClg, 2OmM HEPES, pH 7.5).
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Some ventricles were recorded isotonically, others isometrically.
Doses (400pl) were injected via the 400pl injection loop.
Two (occasionally three) peptides were tested on each ventricle, 
and each peptide pair or triplet was tested on a minimum of five 
ventricles. Roughly equipotent doses of each peptide were 
applied alternately 10 minutes apart. The transducer outputs 
were amplified and recorded on a J-J chart recorder. The percent 
increase in tension or amplitude was plotted against the log of 
the dose, and the potency ratio for the pair of drugs was 
estimated from the linear portion of the plots. Only one series 
of dose-response curves (i.e., one curve for each of the two or 
three peptides being compared) was obtained from each ventricle. 
Materials
Helix aspersa were collected from Kingsbarns, Fife by Mr. J. 
Brown or shipped from California to St. Augustine, Florida by Dr. 
R. Koch or Night Bird Game and Fowl Co. Peptides were purchased 
from Peninsula Laboratories Inc., Cambridge Research Biochemicals 
or Sigma, or were synthesised by the University of Florida 
protein sequence core facility (SGYLAFPRMamide, NDPFLRFamide, 
NDPYLRFamide and SEPYLRFamide) or Dr. J. P. Riehm of the 
University of West Florida (SDPFLRFamide) (Ebberink, Price, van 
Loenhout, Doble, Riehm, Geraerts & Greenberg, 1987). Normal goat 
serum and goat-anti-rabbit conjugated FITC were purchased from 
Boehringer and Mannheim Biochemicals. The antisera S253 and Q2 
were developed and kindly supplied by Dr. D. Price (Whitney Lab, 
University of Florida), and SCPg by Dr. H. Morris (Imperial 
College, London). The remaining chemicals and supplies were 
purchased from Sigma or Fisher.
- 26
Results
Struçture-açtiyitx relationships of S253 and Q2. Since 
these antisera were to be used in the RIAs to identify FMRFamide- 
related peptides in Helix. some measure of their specificity of 
binding was necessary. To satisfy this requirement, the 
structure-activity relationships (SARs) of S253 and Q2 were 
investigated. Exemplary binding curves for each of the two 
FMRFamide antisera are shown in figure 2; the curves were fitted 
by computer; i.e., the method of least squares was applied to the 
data points after log/logit transformation (a Hill plot).
A series of FMRFamide analogues and the two SCPs of Helix 
were tested in RIAs with S253 and Q2, and dose-response curves 
were prepared. The curves and IC^qS are shown in figure 3.
Both antisera are most sensitive to the naturally occurring 
heptapeptides, and they are more sensitive to YGGFMRFamide, a 
synthetic heptapeptide analogue of FMRFamide, than to FMRFamide 
itself. Oxidation of the methionine in FMRFamide increases its 
IC5 0  five to fifty fold. Removing the amide drastically 
reduces the affinity of the antisera to the peptide; indeed Q2 
cannot detect even 50^ il of ImM FMRF and FLRF (SOnmoles) consti­
tuting the entire sample volume of the assay. Neither antiserum 
is particularly sensitive to either of the SCPs, but both 
antisera recognise all the FMRFamide analogues endogenous to 
Helix. At the time that these binding curves were prepared, 
NDPYLRFamide and SEPYLRFamide had not yet been identified so 
these peptides were not included in the survey. Nevertheless,
Q2, in particular, was used in the discovery of NDPYLRFamide and 
SEPYLRFamide (Price, Lesser, Lee, Doble and Greenberg, in prep.).
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Figure 2. Examples of four of the binding curves shown in figure 3 and the computer calculated fit of the line. The curves 
were fitted to the points by computer according to the least squares fit to the log/logit transform equation calculated from the points. The log/logit transformation is also called a Hill plot; log(r/(l-r)) (Y-axis) is plotted against log[D] (X-axis) 
where r is the response as a proportion of the maximum response and [D] is the concentration of drug (peptide). The X-axis displays the peptide content of each assay vial. See figure 3 for a full explanation of the data.
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ICso (moles) Peptide ICso (motes) Peptide
1 3x10'’® pQDPFLRFa 1 7.1 x10’’* pQDPFLRFa
2 7x10*’® NDPFLRFa 2 1.73x10’’° NDPFLRFa
3 1.2x10'’ ^ SDPFLHFa 3 2.64 xiO’’° SDPFLRFa
6 1.27x10 FLRFa 4 3.74X10’’° FLRFa
5 4.47x10'’^ FMRFa 6 6.54 X10’’° FMRFa
7 2.03x10 OX-FMRFa 7 3.04 x10’’ ° OX-FMRFa
4 1.2x10’’ * YQQFMRFa 5 1.9 x10 '° YGGFMRFa
8 1.7x10’” YGGFMRF 9 4x10'® YGGFMRF
9 2.78x10’’° MNYLAFPRMa 8 3.7x10’* SGYLAFPRMa
10 8.5x10’’° SQYLAFPRMa 10 7.2x10’* MNYLAFPRMa
11 7.72x10’° FLRF
12 7.6 XIO’* FMRF
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Figure 3. Binding curves to show the ability of the various peptides to inhibit the binding of the trace, ^^^I-pQYPFLRFamide, to the two antisera S253 and Q2. The curves were fitted to the points by computer according to the least squares fit to the log/logit transform equation calculated from the points. For clarity, the points have not been shown. For both antisera the heptapeptides had a greater affinity for the antiserum than the corresponding tetrapeptide (pQDP-, NDP- and SDPFLRFamide had a greater affinity than FLRFamide and YGGFMRFamide had a greater 
affinity than FMRFamide). Oxidation of the methionine in FMRFamide reduced its affinity for both antisera. Removing the terminal amide from a peptide also reduced its affinity. The main difference between the two antisera is that S253 has a 
greater affinity for FMRFamide than for FLRFamide and Q2 has a greater affinity for FLRFamide than for FMRFamide. The peptides are listed in the same order for each antiserum which is not 
necessarily the order of potency.
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The outstanding difference in the specificities of the two 
antisera is that S253 has a greater affinity for FMRFamide, and 
Q2 has a greater affinity for FLRFamide. (All the known 
endogenous FMRFamide analogues of Helix are recognised by Q2, and 
all but NDPYLRFamide and SEPYLRFamide are additionally recognised 
by S253.) Price (1983) and Lehman and Price (1987) also prepared
some competition curves for the S253 antiserum, but used
iodinated YGGFMRFamide for the trace instead of iodinated 
pQYPFLRFamide. Not surprisingly, the assay was more sensitive to 
FMRFamide and YGGFMRFamide. The advantage of using pQYPFLRFamide 
as the trace is that, by binding less well to the S253 antiserum, 
it increases the sensitivity of the assay. Moreover, it can also
be used with the Q2 antiserum, a practical matter.
Differential distribution of the peptides in cardiac and 
nervous tissue. Acetone extracts of selected Helix tissues were 
separated by HPLC and analysed by RIA. An illustrative HPLC 
separation of standard synthetic peptides is shown in figure 4: 
aliquots containing Inmole of the indicated peptides were 
injected; the UV absorbance (210 and 280nm) of the column 
effluent is displayed. The circumoesophageal ring (brain) 
contains all seven FMRFamide analogues and both SCPs (Fig. 5). 
Moreover, all nine peptides have each been isolated previously 
from the circumoesophageal ganglia and subsequently analysed for 
their emimo acid content if not actually sequenced (see 
Introduction for references). Analysis of the visceral and anal 
nerves combined shows that they, too, contain all nine peptides 
(Fig. 6) as does the anterior aorta (Fig. 7). The SCPs and both 
tetrapeptide amides are present in the heart, but the
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Figure 4. HPLC traces of the UV absorbance (210 and 280nm) of the effluent of the RP-300 column to show the approximate elution times and order of elution of the injected standards (a 
mixture of 1 nmole of each standard was injected onto the column through the injector). This trace was kindly supplied by D. Price.
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Figure 5. RIA analysis of HPLC fractions of acetone extracts of the circumoesophageal ring. A. The peaks identified with S253 antiserum are superimposed upon those identified with Q2. B. The same fractions analysed with SCPg antiserum. All nine peptides 
are present.
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Figure 6. RIA analysis of HPLC fractions of acetone extracts 
of the visceral and anal nerve trunks. A. The peaks identified with S253 antiserum are superimposed upon those identified with Q2. B. The same fractions analysed with SCPg antiserum. All nine peptides are present.
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Figure 7. RIA analysis of HPLC fractions of acetone extracts of the anterior aorta. A. The peaks identified with S253 are superimposed upon those identified with Q2. B. The same fractions analysed with SCPg antiserum. All nine peptides appear to be present.
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heptapeptides are notable for their absence from this tissue 
(Fig. 8). As the third large peak recognised by S253 in the 
heart is not recognised by Q2, it can not be one of the 
identified FMRFamide analogues; i.e., all of them (except 
FMRFamide) contain an antepenultimate leucine residue).
Distribution of iromunoreactivty within the heart and 
nervous system. Immunohistochemistry of the heart with S253 
revealed a diffuse network of nerves evenly distributed through­
out the heart (Fig, 9). Some varicosities can also be seen. The 
staining appears to follow the trabeculae, indicating that the 
fibres are on, or just below, the luminal surface of the heart, 
rather than deeply embedded within the tissue.
Positive staining within the suboesophageal ring was seen in 
two clusters of cell bodies; one in each of the two parietal 
ganglia (Fig. 10). A positively stained bundle of processes can 
also be seen in the visceral nerve as it leaves the ganglion. 
Other workers have stained sections of the central ganglia with 
FMRFamide antisera (Marchand, Wijdenes & Schot, 1982; Cottrell, 
Davies, Turner & Oates, 1988).
The main advantage of immunohistochemistry on wholemounts as 
compared with sections is that the orientation of the intact 
tissue is obvious, and so the different regions of the tissue are 
easily identified. However one possible drawback of wholemounts 
can be seen in the photograph of the atrial-ventricular junction 
(Fig. 9, middle). The atrial wall is much thinner than the 
ventricular wall, so the background fluorescence is much higher 
in the ventricle and the weaker staining is not so visible. The 
suboesophageal ganglia are thicker still (Fig. 10) so only the
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Figure 8. RIA analysis of HPLC fractions of acetone extracts of the heart. A. The peaks identified with S253 antiserum are superimposed upon those identified with Q2. B. The same fractions analysed with SCPg antiserum. Note that the 
heptapeptides are missing.
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Figure 9. Immunohisjbochemistry of the heart with S253 antiserum (wholemount). Atrium (top). A-V junction (middle). Ventricle (bottom). 
Magnification x 100.
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Figure 10. Immunohistochemistry of the suboesophageal ganglia with S253 antiserum (wholemount). 
Magnification x 60.
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very bright staining is obvious. Thus the two groups of stained 
neuronal soma stand out against the background, but the bundle of 
nerve fibres in the visceral nerve are less easily noticed; 
understandably, the single axons leaving each soma are even less 
visible.
One method for overcoming the poor visibility is to clear 
the tissue with xylene or methylsalicylate, a procedure that 
works well with sections. Attempts to clear these wholemounts 
have, however, been unsuccessful. The problem is that the 
tissues must be pinned out before dehydration begins and then 
unpinned before mounting (when they are very fragile), and this 
requires a microscope and lighting. Unfortunately, even a low 
intensity, non-fluorescent light causes the fluorescence to fade 
markedly, thus ruining the preparation.
Finally, S253 does not seem to bind well to the two tyrosine 
analogues (NDPYLRFamide and SEPYLRFamide), so unless these two 
analogues always coexist with one of the other peptides, their 
locations will not be identified by this antiserum.
Calcium-dependent release of the FMRFamide peptides.
The demonstration of the calcium-dependent release of FMRFamide 
peptides from the heart was straightforward (Fig. IIA). A 
tenfold increase in the potassium concentration of the perfusion 
saline had no effect when the calcium content was nominal zero. 
When the calcium level was restored, FMRFamide peptides were 
released when the potassium level was raised (Fig. IIA).
A calcium-dependent release of FMRFamide peptides from the 
brain was more difficult to show (Figs. IIB, 12). Perfusing the 
brain with saline containing nominal zero calcium appeared to
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Figure 11. Demonstration of the release of FMRFamide peptides from the heart (top), and the circumoesophageal ring 
(bottom). The calcium and potassium content of the saline perfusing the tissue at the time of collection of each drop is indicated along the top of each figure. Each bar of the histogram represents the FMRFamide immunoreactivity of a 40pl drop.
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Figure 12. The effect of nominally aero calcium saline on the basal release of the circumoesophageal ring. There is a thirty minute gap between fractions 19 and 20, during which time the basal release has fallen substantially. The basal level does not return to its original value even when the ring is perfused with saline containing the normal calcium concentration.
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cause irreversible damage. In the presence of normal potassium 
levels, zero calcium did not stimulate release; rather, it 
depressed the basal level permanently (Fig. 12). However, 
preincubation in 2mM calcium, in the presence of normal 
potassium, was tolerated by the brain (Fig. IIB). When the 
potassium level was raised tenfold, some release of the peptides 
was observed. Replacing this modified saline with the original 
saline restored the calcium levels and presumably allowed the 
tissue to repolarise. When the potassium level was raised in the 
presence of normal calcium levels the subsequent release was of 
greater magnitude and duration (Fig. IIB).
Comparison of the Actions of the Peptides on the Isolated Cardiac { 
Ventricle
FMRFamide analogues. The effects of the FMRFamide analogues 
on ventricles isolated from aestivating animals were qualitatively 
similar to each other (Figs. 13, 14, 15). Usually, the beat
amplitude rather than the frequency was increased; but effects on 
frequency could sometimes be seen (Fig. 16B), as could increases 
(Fig. 13E) and decreases (Fig. 15B) in tone.
The peptides have different potencies; the potency ratio 
between the least and the most potent being one hundredfold (Fig. 
13C). The five heptapeptide analogues were equipotent (Figs.
13D, 14). Increasing the peptide length increased potency. The
largest potency increase due to the addition of a single residue 
(a factor of eight) accompanied the extension of FLRFamide to 
PFLRFamide (Figs. 15A, B); the smallest such increase (a factor 
of only two) accompanied the subsequent extension of PFLRFamide 
to DPFLRFamide (Figs. 15C, D). The apparent increase in potency
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Figure 13, Pairs (A-C) and triplets (D-E) of approximately equipotent doses of the FMRFamide peptides recorded isometrically, 
400pl of the peptide at the concentration indicated below each dose was injected into the sample loop at the arrows. The five sets of traces are from five different ventricles.
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Figure 14. Triplets of approximately equipotent doses of the tyrosine analogues and NDPFLRFamide recorded isotonically (A,B) 
and isometrically (C,D). 400jul of the peptide at the concentration indicated below each dose was injected into the sample loop at the arrows. The four traces are from four different ventricles. Although the peptides did not necessarily seem equipotent on a particular ventricle, the more potent 
peptide varied with each ventricle. Thus NDPYLRF am i d e is the least potent peptide in record A but the most potent in record D so that, overall, the three heptapeptides are equipotent.
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Figure 15. Pairs of approximately equipotent doses of 
FLRFamide and the synthetic analogues PFLRFamide and DPFLRFamide 
recorded isotonically (A,B) and isometrically (C,D). 400pl ofthe peptide at the concentration indicated below each dose was injected into the sample loop at the arrows. The break in trace C indicates that the doses were not consecutive, though they are shown in the order of application. Records A and B are from one ventricle, C and D are from two others.
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Figure 16. Two sets of responses from the same ventricle to FLRFamide and pQDPFLRFamide. They are recorded isotonically.The ventricle was beating at a sufficiently slow rate for the individual beats to be distinct. There is a break between the two traces. 400pl of the peptide at the concentration indicated 
below each dose was injected into the sample loop at the arrow. 
Although there is no obvious chronotropic effect visible in trace A, there is a positive chronotropic effect in the response to 4 X  IQ-^M pQDPFLRFamide in trace B.
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may not be due solely to the protection against enzyme degradation 
afforded by length increases; i.e., although pQDP-, NDP- and 
SDPFLRFamide are all equipotent, pQDPFLRFamide is N-terminally 
blocked and is therefore completely resistant to degradation by 
amino peptidases. Additionally, these comparisons were made on 
saline-perfused (i.e., no blood) isolated ventricles where the 
action of degrading enzymes should be minimal if present at all.
The FLRFamide heptapeptides could inhibit or even arrest the 
ventricle (Fig. 13E). The tendency of a particular peptide to be 
cardioinhibitory was partly determined by the peptide with which 
it was paired in testing. FMRFamide never arrested the ventricle, 
and FLRFamide never caused arrest when tested with FMRFamide.
But FLRFamide did arrest two of six ventricles when paired with 
pQDPFLRFamide. pQDPFLRFamide arrested only one of six ventricles 
when paired with FLRFamide, but arrested four of six ventricles 
when paired with NDPFLRFamide and SDPFLRFamide (Fig. 13E). The 
significance of these observations is unknown at present; the 
possible interdependence of the peptide actions requires further 
experiments.
SCPs. The responses of the ventricles to the SCPs were 
qualitatively and quantitatively distinguishable from those to the 
FMRFamide analogues (Fig. 17). The two SCPs elicited very similar 
responses, though SGYLAFPRMamide was consistently about three 
times more potent than MNYLAFPRMamide. As these two peptides 
were standardised to each other by HPLC (D. Price, personal 
communication) this difference, though small, is probably reliable. 
At low doses, the SCPs increased the beat amplitude and often 
decreased tone. Chronotropic effects were not observed.
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Figure 17. Pairs (A-C) of approximately equipotent doses of the SCP and FMRFamide peptides recorded isotonically (A) and isometrically (B-D). 400pl of the peptide at the concentrationindicated below each dose was injected into the sample loop at the arrows. The break in the trace indicates that the doses were 
not consecutive, though they are shown in the order of application. D. The 10“°M dose of SGYLAFPRMamide and 4 x 1 0 “'^  dose of FLRFamide 
were approximately equipotent. The 10"'M dose of SGYLAFPRMamide arrested the ventricle but did not seem to affect the subsequent FLRFamide response. Each of the four records is from a different ventricle.
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Comparison of the effects of FMRFamide analogues and SCPs. 
SGYLAFPRMamide was also compared with FLRFamide and pQDPFLRFamide 
(Figs. 17B, C); these records illustrate the dissimilar effects 
of the SCPs and the FMRFamide analogues. The SCP responses were 
more sustained at their pesik (i.e., they were more rounded at the 
top) than those of the FMRFamide analogues (more pointed 
responses) (Figs. 17B, C). They may also show split peaks at 
higher doses (Fig. 17D). The SCPs often reduced diastolic tone, 
whether the recording was isotonic or isometric (Figs. 17A, C). 
Like the heptapeptides, they could inhibit and arrest the 
ventricle (Fig. 17D). The eight minute arrest caused by 
SGYLAFPRMamide in figure 17D had no obvious effect on the 
subsequent FLRFamide response, so the SCPs may act through a 
different mechanism on the ventricle than that of the FMRFamide 
analogues.
Occasionally some equipotent pairs of responses displayed 
more obvious qualitative differences. Some examples are shown in 
figure 18. The height of the sharp initial peak was measured in 
the determination of the response of the ventricle to these 
particular doses of peptide. However, secondary shoulders could 
sometimes be seen following these initial peaks. These shoulders 
were more prominent in one member of the pair than the other.
Figure 19 summarises the potency ratios between the different 
peptides on the isolated ventricle from aestivating Helix.
Comparison of the relative potencies of FMRFamide and 
FLRFamide on ventricles from aestivating and active animals.
The responses of four ventricles to FMRFamide and FLRFamide can 
be seen in figure 20: A-C were ventricles from active animals; D
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Figure 18. Pairs of approximately equipotent doses of FMRFamide peptides applied to three isolated ventricles from aestivating Helix. 400pl of the peptide at the concentration 
indicated below each dose was injected into the sample loop at 
the arrows. Small qualitative differences between the members of each pair can be seen (mainly whether or not a shoulder is obvious in the response).
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Figure 19. The relative potencies of the peptides on the 
isolated ventricle from aestivating Helix aspersa. The order of 
potency decreases from top to bottom.
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Figure 20. Pairs of approximately equipotent doses of FLRFamide and FMRFamide applied to isolated ventricles from active (A-C) and aestivating (D) Helix. 400pl of the peptide at 
the concentration indicated below each dose was injected into the sample loop at the arrows. Record D is the same as that in figure 13A. Records A and B are from one ventricle, C and D are from two other ventricles.
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was from an aestivating animal and is the same record shown in 
figure 13A. A comparison of parts C and D, both from isometric 
recordings, reveals no obvious qualitative difference, either 
between the two peptides, or between the two states of activity. 
Likewise parts A and B are similar; the increase in tone observed 
was probably more a function of the isotonic recording than the 
state of the animal. Table 3 lists the potency ratios (mean +/- 
the standard error of the mean) of the peptide pairs tested; the 
more potent analogue is listed first.
Peptide pair N mean +/“ s.e.m.
AESTIVATINGSGYLAFPRMamide/FLRFamide 5 59.806 +/- 13.188SGYLAFPRMamide/pQDPFLRFamide 5 7.948 +/- 3.614SGYLAFPRMaraide/MNYLAFPRMamide 5 2.798 +/- 0. 169pQDPFLRF amide/FMRFamide 3 97.72 +/“ 25.63pQDPFLRFamide/FLRFamide 6 9.288 +/- 1. 236DPFLRFaraide/PFLRFamide 5 1.853 +/- 0. 236PFLRF amide/FLRF amide 8 8. 379 +/- 1. 925FLRFamide/FMRF amide 5 11.694 +/- 2.63
ACTIVEFLRFamide/FMRFamide 5 4.89 +/“ 0. 623
Table 3. The mean +/- standard error of the mean (s.e.m.) for each peptide pair tested on isolated Helix ventricles. The 
first eight pairs were tested on ventricles from aestivating animals, the final pair was tested on ventricles from active animals. N is the number of ventricles considered in the calculation of the mean and standard error for each pair.
The potency ratios for FLRFamide and FMRFamide on ventricles 
removed from aestivating animals was 11.694 +/- 2.63, while that 
for ventricles removed from active animals was 4,89 +/- 0.623. 
Analysis of these differences with the Students T-test showed
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that this difference is significant at p<0.001; i.e., the 
probability that both sets of data are from the same population 
is less than one in one thousand.
Dose—response curves. A selection of dose-response 
curves are shown in figure 21. The straight sections of the 
curves are approximately parallel for each set of responses.
Each peptide was added over a set concentration range which had 
been previously determined to include the dose that gave a 
maximal or near-maximal response, or (in the case of the 
tetrapeptides) a rather high concentration (4 x lO'^M) had 
been reached. Comparison of two or more curves for the same 
peptide reveals the variety of ventricular response. For 
example, SGYLAFPRMamide elicited a "classical" curve in figure 
2IB and F, evoked reduced excitation in figure 21C and arrested 
the ventricle in figure 21A. The maximal response was not easy 
to define in the presence of inhibition and cardiac arrest, and 
the maximal responses were often not the same for both members of 
a particular pair of peptides (Fig. 21A). SGYLAFPRMamide 
arrested the ventricle in figure 21A so its curve is incomplete, 
and pQDPFLRFamide arrested the ventricle in figure 21H so both 
curves are incomplete. The remaining curves are complete. Thus 
it seemed that the most simple and objective criterion to compare 
between peptides was the equipotent dose using the linear section 
of the curves.
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Figure 21. Dose-response curves for the endogenous peptides on ventricles from aestivating Helix (A-F, H,I). All the curves 
for a set are from the same ventricle though each set is from a different ventricle. Set G is from a ventricle from an active animal. The X-axis is constant but the Y-axis (% increase in beat strength or amplitude) varies between sets. SGYLAFPRMamide arrested the ventricle in set A so its curve is incomplete. pQDPFLRFamide arrested the ventricle in set H so both curves are incomplete. The remaining curves are complete and show that while the linear portions of the curves are parallel, the maximal response was not always evoked, though it was exceeded in some curves where higher doses elicit sub-maximal responses.
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Discussion
Summary of the evidence. The nine endogenous peptides 
of Helix are all active on the isolated Helix ventricle, but they 
are not equipotent. The tetrapeptides are the least potent; the 
SCP nonapeptides are the most potent; and the heptapeptides, 
equipotent with each other, are of intermediate potency. Immuno- 
histochemical staining with FMRFamide antisera reveals a diffuse 
nerve network in the Helix heart, two clusters of cell bodies in 
the suboesophageal ganglia, and nerve processes in the visceral 
nerve. Analysis of these tissues by HPLC and subsequent RIA 
shows that all of the peptides are present in the central nervous 
tissues, but that the heptapeptides are missing from the heart. 
The mean concentration of pQDPFLRFamide in the blood of Helix 
aspersa is 3~7nM (Price, Cottrell, Doble, Greenberg, Jorenby, 
Lehman & Riehm, 1985). The calcium-dependent release of 
FMRFamide-immunoreactive material from both the heart and the 
circumoesophageal ring suggests that these peptides may be 
released from these two organs under physiological conditions.
Effects of FMRFamide and possible presence of an analogue 
in the anterior aorta. Positive staining with a FMRFamide 
antiserum has been observed in the outer, longitudinal layer of 
the anterior aorta of Helix aspersa. but this layer is 
unresponsive to synthetic FMRFamide in organ bath experiments.
In contrast, the inner, circular muscle contracts in the presence 
of FMRFamide, but does not exhibit positive staining with 
FMRFamide antiserum (Griffond, Boer & Wijdenes, 1986), The 
authors propose that the active substance is carried to the outer 
muscle layer in nerves, whence it is released in a non-synaptic
- 58 -
manner, to diffuse to the circular layer where it exerts its 
effect. The actual substance (if, indeed there is only one) has 
not been identified, and it could be any of the endogenous 
FMRFamide analogues: all seven have been extracted from the 
anterior aorta in acetone, and all have been identified by HPLC 
and RIA analysis; but their actions on the aorta have not yet 
been compared. Thus, in addition to strengthening the heartbeat, 
the FMRFamide peptides could influence the regulation of blood 
flow at least in the anterior aorta, if not the circulatory 
system in general.
Possible route of delivery of the tetrapeptides to the 
heart. The tetrapeptides may be acting as neurotransmitters on 
the heart. They could be synthesised in the circumoesophageal 
ganglia and transported to the heart in neurones running in the 
visceral nerve and thence to the cardiac nerve. The cardiac 
nerve branches out, providing a diffuse innervation along the 
luminal surface of the heart. Here, the tetrapeptides would be 
released, in a high local concentration, from varicosities or 
terminals in close apposition to protected, postjunctional 
receptors. The tetrapeptides would thus be acting on the cardiac 
muscle at neuromuscular junctions.
Suggest^ route travelled by the heptapeptides from the 
brain to the heart. The heptapeptides are not present in the 
heart, but they have been detected at nanomolar levels in the 
blood. The aorta enters the suboesophageal ganglia, divides to 
supply the individual ganglia, then ramifies into the connective 
tissue sheath, eventually forming an almost continuous blood- 
filled space lying very close to the surface of the nervous
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tissue (Pentreath & Cottrell, 1970). These data suggest that the 
heptapeptides could be neurohormones. If so, they would be 
secreted from the brain into the blood, and travel in the 
circulation to the heart. There they exert their effect via 
receptors that would be relatively exposed to the blood and 
particularly sensitive to the heptapeptides.
SCPs
Distribution of the SCPs within the central nervous 
system. The SCPs have been extracted from the brain and are 
also present at low levels in the heart. However, their 
distribution within the heart is unstudied, and their calcium- 
dependent release has yet to be demonstrated from any organ in 
Helix.
Immunohistochemistry of the molluscan central nervous system 
indicates that the SCPs are present mainly in the buccal ganglia; 
their levels in other central ganglia are small. The buccal 
ganglia of Helisoma exhibit positive staining with SCP antisera 
(Murphy, Lukowiak & Stell, 1985). Positive staining in the 
cerebral ganglia as well as the buccal ganglia has been 
demonstrated in Tritonia (Kempf, Masinovsky & Willows, 1987). 
Comparison of the immunoreactivity of the various ganglia in 
Aplysia brasiliana using RIA shows that SCP-immunoreactivity is 
highest in the buccal ganglia (75pmoles/pair), followed by the 
pedal (23pmoles), cerebral (IBpmoles), pleural (9pmoles) and 
abdominal ganglia (6.8pmoles) (Lehman, Price & Greenberg, 1984). 
The buccal ganglia of Aplysia californica contain approximately 
ten times the amount of SCPs found in any of the other central 
ganglia (Lloyd, Mahon, Kupfermann, Cohen, Scheller & Weiss,
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1985) .
Presence of SCPs in the visceral and anal nerves. RIA
analysis of HPLC fractions of the visceral and anal nerves 
combined indicates the presence of both SGYLAFPRMamide and 
MNYLAFPRMamide in these nerve trunks. In addition to innervating 
the gut, the visceral nerve also branches off into the cardiac 
nerve. Some of the SCP immunoreactivity may have been derived 
from the cardiac nerve; an HPLC/RIA analysis of the cardiac nerve 
alone might resolve this issue. Since however, this nerve 
branches off the visceral nerve quite close to the heart, two 
difficulties are presented. First, the dissection of this rather 
fragile piece of tissue would be difficult. Second, except for a 
very short length, the nerve is either within the main visceral 
trunk, or within the aorta (in which it appears to arborise very 
quickly to innervate the proximal anterior aorta and the heart).
Two hypotheses conoerning the distribution of SCPs in the 
nervous system and their potency on the heart. The SCPs might 
travel from the brain to the heart by axonal transport. 
Alternatively or additionally, they might travel to the heart in 
the haemolymph.
The SCPs might travel from the brain to the heart by axonal 
transport. Transport could be via the cardiac nerve, but 
arborisation could be restricted until the axons reached the 
atrial-ventricular junction. There, they could then arborise and 
terminate non-synaptically. In the presence of an appropriate 
stimulus, the SCPs would be released, but their receptors might 
be on the luminal surface of the ventricle rather than within the 
atrial-ventricular junction.
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Thus, the SCPs would arrive at the heart along a neural 
pathway, but would then act hormonally. This mode of delivery 
would be consistent with the low levels of the SCPs within the 
heart and also with the high sensitivity of the ventricle to 
them. As the receptors would be detecting SCPs carried in the 
blood, they would be exposed and sensitive to relatively low 
levels of peptide.
This proposal is supported by the description of a neuro­
secretory system in the atrial-ventricular junction of the Helix 
heart (Cottrell & Osborne, 1969); the vesicles in this neuro- 
haemal site seemed unlikely to contain either 5-HT or dopamine. 
Moreover, the staining observed in this current study with the 
FMRFamide antiserum, S253, was not particularly dense in this 
region. To date, therefore, no transmitter has been positively 
linked with this atrial-ventricular neurosecretory system, but 
the SCPs are reasonable candidates.
Possible link between feeing and heart rate m^iated by 
SCPs. An increase in heart rate associated with feeding has 
been observed in three molluscs: Aplysia californica (Dieringer, 
Koester & Weiss, 1978); Deroceras reticulatum (Duval, 1983); and 
Limax maximus (Grega & Prior, 1985). Lloyd, Kupfermann and Weiss 
(1985) have suggested that the link between feeding and increased 
heart rate may be partially mediated by SCPs spilling over into 
the blood from the digestive tract, but these peptides could not 
be detected in Aplysia haemolymph. However, neither was Lloyd 
able to detect SCPs in Helix heart using the same for bioassay 
(Lloyd, 1978a), though evidence has been presented here that two 
SCPs are extractable from Helix heart. The SCPs might enter the
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circulation from the gut quite close to the heart. The peptides 
would then be at sufficient levels to excite the heart, but would 
be diluted by the haemolymph to undetectable levels downstream 
from the heart. This may also explain why Price (1987) was 
unable to detect SCP immunoreactivity in Helix haemolymph.
The immunohistochemistry, the RIA and the physiological data 
taken together suggest both hypotheses play a part in describing 
the physiological role of the SCPs in Helix. The SCPs may take a 
neural route directly to the heart, and also a circulatory route. 
Whatever the pathway followed, upon arriving at the heart they 
would then act as hormones.
Comparison of the Responses to the FMRFamide Analogues and the 
SCPs
Mechanisms of peptide action. What of the mechanisms by 
which these peptides act upon the heart? The responses induced 
by the FMRFamide analogues are clearly distinguishable from those 
induced by the SCPs, and the eight minute arrest of the ventricle 
by SGYLAFPRMamide did not appear to affect the subsequent 
FLRFamide response in figure 17D. Thus, these two groups of 
peptides probably act through different mechanisms.
The set of responses induced by the various FMRFamide 
analogues are relatively more uniform, but, they are not 
identical. For example, the response to pQDPFLRFamide (Fig. 17B) 
has more of a shoulder than that to FLRFamide (Fig. 17C), even at 
doses that are approximately equiactive. Similarly, the response 
to pQDPFLRFamide in figure 16B has a more rounded peak than the 
adjacent responses to FLRFamide. Finally, there are qualitative 
differences in all the pairs of responses shown in figure 18.
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The slightly slower response of the ventricle to pQDPFLRFamide 
has also been noted by Price, Cottrell, Doble, Greenberg,
Jorenby, Lehman and Riehm (1985).
In summary, these peptides are probably not all acting 
through the same mechanism and there could well be more than one 
component to a response as evidenced by the shoulders seen in the 
responses of figure 18.
Use of the patch-clamp technique. The cellular mechanisms 
of cardiac action of these peptides must be left to speculation 
if only the experiments described here are considered. Several 
issues have not been addressed: the ions involved in the responses 
to the different peptides; the site of peptide action whether on 
receptor-mediated ion channels or upon receptors linked to ion 
channels through second messengers, and the diversity of such 
agents.
The patch-clamp technique (Hamill, Marty, Neher, Sakmann & 
Sigworth, 1981) may be able to answer some of these questions. 
First the ventricular and atrial cells would have to be 
dissociated separately. Whole-cell recording from these cells 
would quickly show if the peptides affected the membrane current 
or potential. If so, application of the peptides to isolated 
patches would allow the channels affected by each peptide to be 
characterised, and bath application of the peptides to cells in 
the cell-attached patch configuration would reveal whether any 
second messengers were involved. If so, these second messengers 
could be identified by the use of isolated patches. The ionic 
mechanisms by which each peptide effected its response could be 
determined by almost any combination of the patch configurations
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once the channels affected by each peptide had been identified.
Voltage clamp techniques have been used successfully on 
dissociated leech heart muscle cells; they are depolarised by as 
little as FMRFamide in the bathing saline (Thompson &
Calabrese, 1988). Preliminary results seem to implicate the 
involvement of calcium in the response.
Physiological Significance of the Different Peptides
Do the effects of these peptides on the isolated ventricle 
and their distribution within the central nervous system tell us 
anything about their physiological significance?
The heptapeptides. There are five heptapeptides present 
in Helix and all are equipotent on the isolated ventricle from 
aestivating snails. This finding is not consistent with those 
from a study of the potencies of a series of peptides on the 
radula protractor of Busycon contrarium and the heart of 
Mercenaria mercenaria (Greenberg, Payza, Nachman, Holman & Price, 
1988). FMRFamide was assigned a value of 1.0, and all the other 
peptides were standardised against FMRFamide. When the 
N-terminal phenylalanine was replaced by a tyrosine (YMRFamide; 
i.e., an hydroxyl group was added), the potency fell from 1.0 to 
0.3 (radula protractor muscle) and from 1.0 to 0.14 (Mercenaria 
heart). However, a similar change in the heptapeptide sequence 
(i.e., from NDPFLRFamide to NDPYLRFamide) did not affect the 
potency of the peptides on the Helix ventricle.
These contrasting observations —  the differing potencies of 
the tetrapeptides on the two muscles vs. the equipotency of the 
heptapeptides on the Helix heart —  suggest that the radula 
protractor and the clam heart have receptors different to those
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of the Helix heart. Alternatively, this change is a terminal 
change for the tetrapeptides (occurring at the N-terminal end of 
the peptide) where it might be rather exposed and so important to 
the receptor while the change is in the middle of the hepta­
peptide where it might be masked and not be so important to the 
receptor. That is, the heptapeptide receptor may only require an 
aromatic residue in this position and it may not matter whether 
this residue is phenylalanine, tyrosine or tryptophan. The 
appropriate tyrosine heptapeptides have not been tested on the 
radula protractor muscle or the clam heart and only the 
endogenous tyrosine analogues have been tested on the isolated 
Helix ventricle. Perhaps other Helix muscles or neurones can 
distinguish between these five heptapeptides.
Comparison of the relative potencies of FMRFamide and 
FLRFamide on ventricles from aestivating and active animals.
All the peptide pairs were initially tested on ventricles removed 
from animals that had been aestivating for several months.
However, one peptide pair was also tested on ventricles removed 
from animals that had been active for at least a week immediately 
before their removal. The responses of ventricles from active and 
aestivating Helix to FLRFamide and FMRFamide are qualitatively 
similar, but quantitatively different. The order of potency is 
the same, but the potency difference is 11.694 +/- 2.63 (mean +/- 
s.e.m.) for aestivating animals and 4.89 +/- 0.623 for ventricles 
from active animals. This difference is significant at p<0.001 
using the Student's T-test. Thus, the relative sensitivity of 
the isolated Helix ventricle to FMRFamide and FLRFamide is partly 
dependent upon the state of the animal from which it is removed.
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The mechanism behind this observation is not known at present.
Relative levels of FMRFamide analogues and state of 
activity. Lehman and Greenberg (1987) have proposed that the 
relative levels of FMRFamide and pQDPFLRFamide in Helix blood, as 
well as the antagonistic actions of the peptides, determine the 
state of activity of the animal. In short, rising levels of 
pQDPFLRFamide arouse the animal while rising levels of FMRFamide 
cause it to withdraw into its shell. Further investigations of 
this hypothesis should include a comparison of the relative 
potencies of the peptides on ventricles from active animals, and 
on their vasculatures, and more precise data on the levels of the 
individual peptides in the haemolymph of animals in various 
states of activity.
Haemolymph samples from different regions of the circulation 
might provide further information regarding the distribution, if 
any, of the SCPs in the haemolymph. An alternative method for 
determining if circulating levels of SCPs are affected by the 
presentation, ingestion or digestion of food with concomitant 
stimulatory actions on the heart, would be to inject SCP antibodies 
into the circulation at the time of presentation of food.
Presumably circulating SCPs would be bound and changes in the 
action of the heart in the presence and absence of the circulating 
antibodies could be measured. This would not be a particularly 
easy experiment, and some of the other protocols suggested or 
outlined above would also require much patience, imagination and 
determination. However if they helped to elucidate the 
physiological roles and mechanisms of action of these peptides in 
Helix, the effort would have been substantially repaid.
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CHAPTER TWO
ACTIONS OF FMRFamide ANALOGUES ON THE SYSTEMIC VENTRICLE OF Eledope oirrosa. AND THEIR POSSIBLE PRESENCE 
IN THE CENTRAL NERVOUS SYSTEM
Introduction
Background. Molluscan cardioregulation has attracted 
the interest of experimental biologists for more than a century, 
and the cephalopod heart and circulation have been among the 
topics investigated. Early work focused on the comparative 
anatomy and innervation of the hearts (Ransom, 1884; Fry, 1909). 
Much later, Alexandrowicz noted the unusually dense innervation 
of the anterior vena cava, and further anatomical investigation 
prompted him to suggest a neurosecretory role for it in Eledone 
oirrosa. Sepia officinalis and Octopus vulgaris (1964, 1965).
Bioactivity of cepfaalopod extracts. Berry and Cottrell 
(1970) prepared extracts of the anterior vena cava from Eledone 
oirrosa and applied them to the isolated systemic heart of the 
same species. The response was an increased amplitude and 
frequency of beat. They found that the activity was heat stable, 
and not attributable to 5-HT, adrenaline or nor-adrenaline.
Blanchi, Noviello and Libonati (1973) extended these 
experiments, testing vena cava extracts from several cephalopods 
on the isolated hearts. Cardioactive extracts could be isolated 
from every species investigated. The extracts were stable to 
heat and pronase, but not to trypsin or papain. Moreover, an 
extract from any of the three octopods investigated (Octopus 
vulgaris. 0. macropus and Eledone moschata) was equally effective 
on the hearts of all three species. The medium bathing the 
isolated venae cavae became cardioactive when the organ was 
electrically stimulated, and the response of the hearts to these
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extracts was similar to the response to the "chemically isolated" 
extracts. Extracts of the vena cava also stimulated the hearts 
and increased the blood pressure of intact Octopus vulgaris 
(Wells & Mangold, 1980).
Irorounohistochemistry. Immunohistochemistry was called 
into play next. Martin, Froesch, Weber and Voigt (1979) noted 
met-enkephalin-1 ike immunoreactivity in the neurosecretory region 
of the Octopus vena cava; they reasoned that the staining was 
quite specific. Positive staining has since been observed in the 
vena cava with antisera raised against alpha-melanotropin, 
arginine-vasopressin (Martin, Froesch & Voigt, 1980), FMRFamide 
(Martin, Froesch, Kiehling & Voigt, 1981), proctolin, oxytocin, 
neurophysin I and II, rat atriopeptin II (ANF) and leu-enkephalin 
(Martin & Voigt, 1987).
Objectives. FMRFamide had not been sequenced when Berry 
and Cottrell were investigating the effects of vena cava extracts 
on the isolated systemic heart of Eledone, but the extract 
appeared to be peptidic and Octopus nervous tissues were 
positively stained with FMRFamide antiserum. Therefore, an 
investigation of the effects of FMRFamide and its analogues on 
the isolated systemic heart of locally available Eledone oirrosa 
was initiated. Additionally, tissue extracts were collected for 
initial analysis by HPLC and RIA; the aim was to identify the 
active substances of the vena cava and other tissue extracts.
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Methods
Dissection of Systemic Heart and Tissues for Biochemical Analysis
Dissection of heart and vena cava. Eledone oirrosa were 
caught in the North Sea off the Fife coast. They were 
transported to the Gatty Marine Laboratory in covered, water- 
filled containers, transferred to covered aerated tanks, and 
allowed a few days to recover from their ordeal. As each animal 
was required, it was recaptured, transferred to the experimental 
laboratory, left to rest for thirty to sixty minutes, and 
anaesthetised with magnesium chloride solution (Messenger, Nixon 
& Ryan, 1985). The mantle septum was quickly severed so that the 
mantle could be reflected to expose the internal organs.
The vena cava was transected immediately exterior to the 
cartilage enveloping the brain, and the brain in its case was 
severed from the rest of the body and set aside (see next 
section). The vena cava was dissected free for approximately 
three-quarters of its length to the branchial hearts. It was 
then weighed and placed in a stoppered container with four times 
its mass of acetone.
The systemic heart was then carefully dissected free; the 
thin pericardial membrane was removed from around the ventricle. 
The left efferent branchial vessel was cannulated, the tip of the 
cannula being within the ventricle itself. The right branchial 
vessel was ligated, and the smaller gonadal artery and abdominal 
aorta were either severed at a distance from the heart so that 
they folded and sealed shut, or were ligated. The anterior aorta 
was freed for a length of approximately two centimeters from the
70
heart. An incision was made in the wall severing it halfway and 
a length of strong cotton thread tied in this nick so that the 
vessel was not blocked to the flow of liquid. The aorta was 
severed distal to this tie. (Nomenclature is that of Isgrove 
(1909).)
The cannula with its tip in the ventricle was connected to 
the perfusion system with a silicone tube so that the heart was 
freely suspended (Fig. 22). The flow of decanted sea water was 
initiated and set at a rate just fast enough to permit a small 
overflow to bath the external surface of the heart. The thread 
from the anterior aorta was fastened to a drinking straw which 
magnified the beat. At the far end of this straw was a glass pen 
which could be positioned against the side of a smoked drum to 
record the rate and amplitude of the beats.
Dissection of the brain and optic lobe for analysis.
While the ventricle was left to beat and equilibrate for thirty 
minutes, the main brain and optic lobes were dissected from their 
cartilaginous case. They were weighed separately and placed in 
separate stoppered containers with four times their mass of acetone. 
These tissues were then stored at -20'^ C until required for HPLC. 
Comparison of the Effects of the Peptides on the Isolated Ventricle
Apparatus. Sea water flowed from a reservoir through 
silicone tubing almost to the heart (Fig. 22). Just before 
arriving at the heart, the tubing was interrupted by a glass 
Y-piece. The tubing was connected to one of the top arms and the 
bottom arm. A short length of tubing connected the bottom arm to 
the cannula. The purpose of the second top arm was twofold; it 
maintained a constant head of pressure because it was open to the
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reservoir
heart
smokeddrum
Figure 22. A diagram of the open tubing arrangement for the 
comparison of the potencies of some FMRFamide analogues on the isolated Eledone ventricle. The peptides were injected as a bolus through the wide vertical tube which was open to the air and thus at atmospheric pressure.
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atmosphere, and it was through this arm that each bolus of 
peptide was injected.
Application of the peptides. Stock solutions of peptide 
at a concentration of no less than 10~^M in decanted sea water 
were made and stored at -20°C. For testing, serial tenfold 
dilutions were made to the required concentration. At ten minute 
intervals, a bolus of 0.1, 0.2 or 0.4ml peptide solution was 
injected into the Y-piece. Nineteen gauge, 1.5 inch needles were 
used so that the injection could be made rapidly and almost 
directly into the lumen of the ventricle. Care was taken to 
disturb the preparation as little as possible.
Although the systemic heart was removed from the animal, 
only the ventricle could respond to the peptides. The cannula 
was inserted straight through the left atrium into the ventricle 
and the right atrium was ligated with the right efferent 
branchial vessel.
Optimum size of animal. The carcass was weighed and 
comparison of the performance and life span of the isolated heart 
with the mass of the animal from which it was removed revealed 
that the most reliable and useful hearts were those from animals 
with a mass of 200-400g.
Detection of immunoreactive peaks with FMRFamide antisera
The three vials with their tissues were transported to the 
Whitney Laboratory in a vacuum flask filled with dry ice. There, 
the acetone was decanted off and the tissue washed with several 
volumes of acetone. The acetone was pooled with the dissolved 
extract. The acetone was then evaporated off with a rotary 
evaporator connected to a water aspirator in a water bath heated 
to 65^0, The remaining liquid was diluted with HPLC buffer A
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and centrifuged to sediment any particles. The extract was 
separated by HPLC, and the fractions tested for immunoreactivity 
with the S253, Q2 and SCPg antisera as for the Helix tissue.
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Results
Responses of the Isolated Ventricles to the Peptides
Shape of response. All of the FMRFamide analogues tested 
stimulated the isolated ventricle (Fig. 23); an initial sharp 
increase in the beat amplitude was often followed by a secondary 
shoulder that was more slow to develop and decline. The responses 
shown have been chosen for their equipotency, and both members of 
a pair are from the same ventricle, but not all the responses 
were qualitatively similar. The response to a bolus of FLRFamide 
had a more obvious shoulder than that to FMRFamide (Fig. 23A).
The shoulders of the responses to the extended analogues were 
more slow to develop than those of the responses to FMRFamide (Fig. 
23B and C); the shoulder of the NDPFLRFamide was the slowest to 
develop (Fig. 23C). The rapid fading of the responses in figure 
23B was probably more a function of that particular ventricle (it 
had a very shallow beat) than the peptides. Thus, while the 
responses of that ventricle to FMRFamide and YGGFMRFamide can be 
compared, comparison of these two particular responses with those 
from another ventricle would be inappropriate.
Relative potencies. The relative potency differences of 
the peptides on the isolated systemic ventricles are summarised 
in figure 24. In short, extending the peptides at the 
N-terminal, from four residues to seven, decreased their potency 
on the ventricle. The greatest potency difference (a factor of 
240) is that between FMRFamide and the extended leucine analogue, 
NDPFLRFamide; FMRFamide is only four times more potent than 
FLRFamide. As with the Helix ventricle, not all the peptides
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Figure 23. Pairs of approximately equipotent doses of peptides applied to the isolated ventricle of Eledone oirrosa.The peptides were applied at the arrows as a bolus containing the number of moles of the peptide indicated below each dose. Each 
of the four records is from a different ventricle.
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Figure 24. The relative potencies of the peptides on the 
isolated ventricle of Eledone. The order of potency decreases 
from top to bottom.
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Figure 25. Two sets of dose-response curves for the peptide: on the isolated ventricle of Eledone. All curves for a set are 
from the same ventricle, but each set is from a different 
ventricle.
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Figure 26. RIA analysis of HPLC fractions of acetone extracts of the optic lobe (top), brain (middle) and vena cava (bottom) from Eledone oirrosa. The peaks identified with S253 
are superimposed upon those identified with Q2 (left). The same 
fractions are analysed with SCPg antiserum (right).
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evoked the same maximum response from a given ventricle (Fig.
25). Thus, the relative potencies of the peptides on the Eledone 
ventricle were determined by comparing equipotent doses.
All four peptides were tested on a minimum of three 
ventricles. FMRFamide and FLRFamide, being the most potent, were 
compared on seven ventricles. However, only three ventricles 
were sensitive enough to respond to more than just the highest 
dose of NDPFLRFamide.
RIA Analysis of the Extracts
All three tissues displayed six peaks immunoreactive to both 
S253 and Q2; the peaks had similar elution times on the same HPLC 
gradient (Fig. 26). Because the six peaks in all three tissues 
were identified by both S253 and Q2, FMRFamide, or one or more of 
its analogues, is probably present, though this is not certain. 
Comparison of the Eledone peaks with those of Helix indicates 
that the first two Eledone peaks could be FMRFamide and FLRFamide, 
respectively. The two Octopus pentapeptides, AFLRFamide and 
TFLRFamide, could also be present in Eledone. though their 
elution times with the HPLC gradient used here are not known.
The fractions concerned have been saved, and potential analogues 
synthesised; after further purification the relevant peptides 
will be identified by fast atom bombardment spectroscopy and 
sequence analysis.
The peaks identified with SCPg antiserum were less 
distinct and their level of immunoreactivity was very low (Fig.
26) so they have been discounted for the present as their 
validity is in doubt.
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Discussion
Responses of Cephalopod Hearts to FMRFamide Analogues
Eledone ventricles. All the FMRFamide analogues tested 
elicited responses from the isolated systemic ventricle of 
Eledone. However, they were not equipotent, nor were their 
effects identical. The order of potency of the FMRFamide 
analogues on the Eledone ventricle is the reverse of that on the 
Helix ventricle, but the significance of this relationship 
remains obscure.
Comparison of Octopus and Eledone. FMRFamide, FLRFamide, 
YGGFMRFamide and YGGFLRFamide all had positive effects on the 
frequency and amplitude of the beat of the isolated systemic 
heart of Octopus vulgaris (Voigt, Kiehling, Froesch, Schiebe & 
Martin, 1981). The frequency effects of the analogues tested on 
the Eledone ventricle were, however, slight and secondary to the 
amplitude effect.
Mechanism of the responses. Two qualitative differences 
in the responses were observed: the FLRFamide-evoked response had 
a more prominent shoulder than that of FMRFamide; and the 
shoulders on the responses elicited by the extended analogues 
were slower to develop than those elicited by FMRFamide. These 
differences suggest a diversity of mechanisms of action; e.g., 
different ionic channels, second messengers, or other intra­
cellular mechanisms could be involved. However, the results, 
though intriguing, are insufficiently developed to support 
speculation. As with the Helix ventricle, further experiments 
are required.
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FMRFamide analogues endogenous to cephalopods. All the 
FMRFamide analogues tested on the ventricle or other tissues of 
Helix are, indeed, endogenous to it. In contrast, information 
about Eledone. whether biochemical or pharmacological, is 
incomplete.
Octopus vulgaris has been the most popular cephalopod for 
the type of experiments discussed here. This may be due, in 
part, to its larger size and its greater availability to those 
interested in cephalopods. Peak C (the impure "precursor" of 
FMRFamide) was isolated from the brain, optic lobes and systemic 
heart of Octopus bimaculatus (Agarwal, Ligon & Greenberg, 1972). 
More recently, FMRFamide, FLRFamide, AFLRFamide, TFLRFamide and 
YGGFMRFamide have been identified in extracts of the nervous 
tissue of Octopus vulgaris (Martin & Voigt, 1987; Voigt & Martin,
1986), though the authors have some reservations concerning 
YGGFMRFamide (Martin & Voigt, 1987).
Care should be taken when drawing analogies between Octopus 
and Eledone. The identification of a peptide in one species does 
not ensure its presence in another. For example, GDPFLRFamide is 
to be found in Siphonaria (Price, Cobb, Doble, Kline & Greenberg,
1987), but not in Helix.
Immunoreactive Fractions from Eledone Tissue
This investigation of the actions of the FMRFamide analogues 
on the Eledone systemic ventricle began before data was published 
concerning the possible presence of these analogues in Octopus. 
Two goals were in mind at that time: the effect of these peptides 
on the ventricle; and (to put the cardioregulatory data in 
perspective) the distribution of these peptides in the vena cava
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and central nervous system of Eledone. Thus the brains (minus 
the optic lobes), the optic lobes and venae cavae were collected 
for acetone extraction and subsequent RIA of the HPLC fractions.
Six immunoreactive peaks seem common to all three tissues.
The fractions composing the six peaks immunoreactive to both S253 
and Q2 have been saved for purification and identification. The 
SCP immunoreactivity seemed too low to pursue. Little more can 
be said about the source of this immunoreactivity with the 
information currently available.
Possible Roles for FMRFamide Analogues in Cephalopods
Main brain and vena cava. Let us for the moment assume 
that FMRFamide or its analogues are present in these tissues.
What could be the possible significance of their presence in all 
three tissues? Their presence in the brain could be explained in 
part by their presence in the vena cava. The vena cava is a 
neurohaemal release site; the neuronal somata reside in the brain, 
the axons project to the vena cava. The peptide precursors are 
probably synthesised in the brain; the peptides are then processed 
as they are transported along the axons.
What of their presence in the vena cava? The cardioactivity 
of the peptides has been demonstrated, and the vena cava is a 
reasonable release site for a substance with such a role. The 
brain could receive the sensory information indicating a need for 
increased cardiac output and so stimulate the release from the 
vena cava of one or more of these peptides which would be carried 
in the blood to the systemic heart producing the required 
stimulation.
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An additional role for FMRFamide has been suggested by 
experiments performed with Sepia officinalis. Le Gall, Feral,
Van Minnen and Marchand (1988) have noted FMRFamide-immunoreactive 
fibres originating in the basal-dorsal lobe and the olfactory lobe 
of the central nervous system. These fibres form an extensive 
network in the inferior part of the dorsal-lateral lobe and 
traverse through the optic tract to innervate the optic gland. 
These lobes are involved in the integration of chemical and 
visual stimuli and the control of reproduction. The identity of 
the antigen is not yet known; nor has FMRFamide itself been 
tested in this system, but the possibility remains that this 
peptide has a role in the control of reproduction in cephalopods.
Optic lobes. What, however, could be the significance 
and purpose of these peptides in the optic lobe? The pharyngeal- 
ophthalmic vein supplies the eye and related tissue. Froesch and 
Mangold (1976) tested extracts of the pharyngeal-ophthalmic veins 
from Eledone on systemic hearts of the same. The extracts were 
cardioactive, but their effects, compared with those of FMRFamide 
and its analogues, were distinctly dissimilar. The extracts 
were, of course, not pure but were mixtures of compounds, any 
number of which could be cardioactive. Thus, although FMRFamide 
or one of its analogues might well have been present, its effect 
would have been grossly modified by those of other cardioactive 
constituents of the extract.
Boycott and Young (quoted in Froesch & Mangold, 1976) 
suggested that the subpendiculate nerve might be involved in 
regulating blood pressure in the eye cavity. Although Froesch 
and Mangold supported this theory in principle, they suggested it
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might be too restricted, and that this regulatory activity might 
be more widespread within the animal.
FMRFamide immunoreactivity associated with eyes in other 
animals. Positive staining with FMRFamide antisera has been 
observed in the eyestalks of the prawn (Jacobs & Van Herp, 1984) 
and crayfish (Van Deijnen, Vek & Van Herp, 1985), and retinal 
cells of the perch (Zucker & Dowling, 1987), goldfish (Stell, 
Walker, Chohan & Ball, 1984; Muske, Dockray, Chohan & Stell,
1987) and frog (Wirsig-Wieohmann & Basinger, 1988). Thus 
FMRFamide could be involved in the control of blood pressure in 
the optic cavity, and the body in general (important for a 
cephalopod which may alter its depth in the water), but it could 
also act as a general ophthalmic transmitter, as suggested for 
crustaceans,
Other Cardioactive Peptides That May Be Associated with Molluscs
The earlier assumption that one or more FMRFamide analogues 
were present in Eledone need not preclude the presence of other 
cardioactive peptides as well. Four mammalian atrial peptides: 
cardiodilatin 1-16, atriopeptin I and II, and atrial natriuretic 
factor 8-33, all affect the systemic heart of Octopus vulgaris 
(Agnisola, Cariello, De Santis, Miralto & Tota, 1989). As yet, 
there is no evidence for their presence in any cephalopod, though 
positive staining with cardiodilatin antiserum has been observed 
in the mollusc Helix pomatia. and atrial and suboesophageal 
extracts relaxed the smooth muscle of rabbit aortic strips in a 
dose-dependent manner (Reinecke, Nehls & Forssmann, 1986).
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other Molluscan Peptides
Catch-relaxing peptide (Ala-Met-Pro-Met-Leu-Arg-Leu-NH2 )  ^
sequenced from pedal ganglia extracts of Mytilus edulis, relaxes 
catch tension of the anterior byssus muscle of Mytilus (hence its 
name) (Hirata, Kubota, Takabatake, Kawahara, Shimamoto & Muneoka,
1987). This peptide also inhibits cardiac contractions in Mytilus 
and two other bivalves (Meretrix lusoria and Tapes japonica).
Histidine-rich basic peptide, 43 amino acid residues long, 
N-terminally blocked, and obtained by molecular genetics from 
Aplysia californica neurones R3-14, induces a dose-dependent 
increase in beat amplitude of the isolated heart and isolated 
ventricle, while the isolated atrium responds with increased beat 
amplitude and frequency (Campanelli & Scheller, 1987).
Three other peptides have been sequenced from Aplysia 
californica. Myomodulin (Pro-Met-Ser-Met-Leu-Arg-Leu-NHg) and 
buccallin (Gly-Met-Asp-Ser-Leu-Ala-Phe-Ser-Gly-Gly-Leu-NHg) have 
been isolated from two neurones that modulate the accesory radula 
closure muscle (Cropper, Tenenbaum, Kolks, Kupfermann & Weiss,
1987; Cropper, Miller, Tenenbaum, Kolks, Kupfermann & Weiss,
1988). Pedal peptide (Pro-Leu-Asp-Ser-Val-Tyr-Gly-Thr-His-Gly-Met- 
Ser-Gly-Phe-Ala) isolated from the pedal ganglia, has a free 
carboxyl terminal (Lloyd & Connolly, 1989). Pedal peptide induces 
net inward currents associated with a decrease in membrane 
conductance in neurones L2, L3 and L5. As the main interest of 
the two laboratories responsible for these three peptides is not 
cardiac physiology, these peptides have not yet been tested on 
hearts.
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Thus all the FMRFamide analogues tested on the isolated 
systemic ventricle of Eledone cirrosa are cardioactive. One or 
more of them may be endogenous to this animal, and so may other 
cardioactive compounds. The identity of the endogenous 
cardioactive substances remains to be demonstrated, as do their 
precise mechanisms of action and their physiological roles.
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CHAPTER THREE
COMPARISON OF THE EFFECTS OF FMRFamide ANALOGUES ON THE CALCIUM CURRENT OF THE Cl NEURONE OF Helix aspersa
Introduction
Actions of FMRFamide Analogues on Helix Neurones
Comparison of effects of FMRFamide analogues on the ionic 
currents of Helix neurones. Cottrell, Davies and Green, (1984) 
and Cottrell and Davies, (1987) compared the ionic effects of 
FMRFamide and some endogenous and synthetic analogues on 
identified and unidentified neurones of the central ganglia of 
Helix aspersa. Two main points arose from their investigations. 
First, four different responses could be evoked by the various 
analogues, but the two groups of analogues (tetrapeptides and 
heptapeptides) were not equipotent for any of these responses. 
Second, a brief survey with the analogues employed revealed 
certain minimum structural requirements for activity. In 
particular, the C-terminal -Phe-amide was required and N-terminal 
extension altered the properties of the peptides, increasing the 
potency for some effects and decreasing it for others.
The response evoked by a particular peptide depended upon 
the particular neurone to which it had been applied and the 
holding potential of that neurone. Some neurones could exhibit 
more than one response (depending upon the peptide and the 
holding potential). In summary, one sodium-dependent response 
and three potassium-dependent responses were seen. One 
potassium-dependent response was due to a voltage- and calcium- 
dependent decrease in the conductance. The remaining two 
potassium-dependent responses and the sodium-dependent response 
were caused by increases in ionic conductance.
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Comparison of effects of FMRFamide and pQDPFLRF amide on 
Helix neurones. Boyd and Walker (1985) examined the effects of 
FMRFamide on a range of neurones in the suboesophageal ganglia of 
Helix aspersa. Cells that were depolarised by ACh were hyper­
polarised by FMRFamide. Experiments manipulating the external 
potassium concentration and the addition of 4-AP to the bath 
suggested this was due to an increase in potassium conductance.
Conversely, cells that were hyperpolarised by ACh were 
depolarised by FMRFamide. Removal of sodium from the bath saline 
abolished the FMRFamide response and hyperpolarising current 
pulses were increased in the presence of FMRFamide. Thus, this 
response was mediated by an increased sodium current in these 
cells. D-tubocurarine, tetrodotoxin, morphine, naloxone and 
met-enkephalin were all without effect.
Cottrell and Davies (1987) found that FMRFamide and 
FLRFamide were equipotent in their effects on the neurones they 
tested (though FIRFamide was sometimes slightly less potent than 
the other two tetrapeptides). Boyd and Walker (1985) concurred 
with them where hyperpolarising (increased potassium conductance) 
responses- were concerned, but differed in their findings with 
sodium responses. "FLRFamide was consistently less potent than 
FMRFamide" in its effect on the F77 cell, though cross­
desensitisation was evident implying that both peptides were 
acting through the same receptor. Cottrell and Davies (1987) 
also observed that the response mediated by increased sodium 
conductance was desensitised by the three tetrapeptides.
Boyd and Walker (1987) went on to compare the effects of 
FMRFamide and pQDPFLRFamide on six identified neurones in the
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suboesophageal ganglia of Helix aspersa. pQDPFLRFamide was 
unable to depolarise any cell tested, even one that was 
depolarised by FMRFamide. Generally, pQDPFLRFamide was less 
potent in its effect upon a cell than FMRFamide. Occasionally 
they were equipotent, as they were on cell E13. Here both 
peptides hyperpolarised the cell, suggesting that the E13 neurone 
described by Cottrell and Davies (in which FMRFamide appeared to 
induce a depolarising sodium current while pQDPFLRFamide was 
apparently without effect) was not the E13 described by Boyd and 
Walker. FMRFamide and pQDPFLRFamide could induce opposing 
effects on the same neurone as they did for F77 where FMRFamide 
depolarised the cell while pQDPFLRFamide hyperpolarised it.
Effect of FMRFamide on other currents in Helix neurones.
A third laboratory developed an interest in FMRFamide and its 
effects on identified neurones in the suboesophageal ganglia of 
Helix aspersa. Colombaioni, Paupardin-Tritsch, Vidal and 
Gerschenfeld (1985) noted the effect of FMRFamide on yet a fourth 
potassium current. FMRFamide was observed to decrease a 
potassium conductance that was not dependent upon intracellular 
free calcium levels (as it was not affected by intracellular 
injections of the calcium chelator EGTA). Instead, it was 
mediated via cAMP (as judged by the effects of cAMP, forskolin 
and IBMX upon the Ell neurone). Intracellular injection of cAMP 
could mimic the actions of FMRFamide on the Ell neurone.
Forskolin (a diterpene activator of adenylate cyclase) and the 
phosphodiesterase inhibitor IBMX both evoked inward currents 
which could not be increased further by FMRFamide. FMRFamide 
also stimulated adenylate cyclase activity in this neurone.
90 -
Combining this evidence the authors proposed that FMRFamide was 
decreasing a cAMP-mediated potassium current in the Ell neurone, 
and that this current was similar to the S-current of Anl.vsia 
sensory neurones described by Klein, Camardo and Kandel (1982).
FMRFamide also decreased a calcium current in the D3, E2 and 
E13 neurones, probably through a second messenger mechanism, but 
not one involving an increase in intracellular cAMP, cGMP or 
calcium levels.
Actions of FMRFamide and YGGFMRFamide on Aplysia neurones. 
FMRFamide and YGGFMRFamide are both equipotent in suppressing a 
voltage-dependent calcium current in particular neurones of 
Aplysia californica (Brezina, Eckert & Erxleben, 1987b). They 
were only able to suppress 30-50% of the total calcium current. 
Though evidence suggested that this suppression was mediated via 
a second messenger, such a messenger has not yet been identified.
While FMRFamide appears to mimic the action of 5-HT on the 
S-current in Helix neurones, it opposes the action of 5-HT on 
neurones in Aplysia californica (Belardetti, Kandel & Siegelbaum, 
1987; Brezina, Eckert & Erxleben, 1987a). Patch-clamp experiments 
have shown that 5-HT reduces the background current in Aplysia by 
a cAMP-dependent closure of S-channels in an "all-or-none" manner. 
FMRFamide (and YGGFMRFamide at equimolar concentrations), however, 
can reverse the closure of these channels by 5-HT or cAMP. They 
increase the probability of each S channel opening using a second 
messenger that is not cAMP.
A second difference in the action of FMRFamide on potassium 
currents in Aplysia as compared to Helix was also noted by Brezina, 
Eckert and Erxleben (1987a). While FMRFamide and YGGFMRFamide
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seem to directly suppress the calcium-dependent potassium current 
in Helix (Cottrell, Davies & Green, 1984), in Aplysia this 
suppression is indirect (Brezina, Eckert & Erxleben, 1987b). 
FMRFamide and YGGFMRFamide have no effect on the calcium-dependent 
potassium current which has been activated by calcium injection 
under voltage clamp; the calcium current is not activated under 
these conditions. However, the peptides do reduce the calcium- 
dependent potassium current which has been evoked by depolarisation 
and hence calcium influx. Thus FMRFamide and YGGFMRFamide are 
suppressing the calcium current which, in turn, suppresses the 
calcium-dependent potassium current; the peptides are not acting 
directly on the potassium current itself. So comparisons between 
Helix and Aplysia need to be made with caution.
The actions of FMRFamide on three identified neurones in the 
left upper quadrant of the abdominal ganglion of Aplysia have 
been investigated by a fifth laboratory. FMRFamide elicits a 
biphasic response from the burster neurones L4 and L6. An 
initial increase in the sodium conductance is followed by a 
subsequent increase in a conductance whose reversal potential 
resembles that of potassium currents. Though this second current 
is neither fast nor particularly transient, it is potassium- 
dependent, unaffected by lOOpM TEA, but blocked by 40-90% by ImM 
4-AP in the bath saline; the same concentration of 4-AP also 
blocked 50-100% of the potassium A current in L4 and L6 (Ruben, 
Johnson & Thompson, 1986).
FMRFamide activates an inward rectifier current in neurone 
L2 which is dependent upon the intracellular chloride concentration 
(Thompson & Ruben, 1988).
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Table 4 summarises the currents in Helix aspersa and Aplysia 
californica that are affected by FMRFamide or close analogues. 
Comparisons have been made between the effects of FMRFamide and 
some close analogues on the sodium and potassium currents of Helix. 
We turn now to a comparison of the action of FMRFamide, FLRFamide, 
and a heptapeptide analogue of each, on the calcium current of 
the Cl neurone of Helix aspersa. Some of these results have been 
previously published in abstract (Cottrell & Lesser, 1987).
1 1 1 1 2 2Hel ix gK
slow gKfast
gNa gK^ gCa gKg
FMRFamide + + N E 4" + — — —  —FLRFamide + + N E + + - X XFIRFamide + + N E + + - X X
pQDPFLRF amide + + N E X XYGGFMRFamide + + + N E X X
3 3 4 4&5 5 6Aplysia gNa gCa ^^Ca gci
FMRFamide + + + + - + + - + +
YGGFMRFamide X X - + + — X
Table 4. A summary of the ionic currents affected by FMRFamideand its analogues in Helix aspersa (top) and Aplysia californica (bottom). The number of + signs indicates the relative potency of the peptide in increasing the current; the number of - signs indicates the relative potency of the peptide in decreasing the 
current; N E indicates that the peptide has no effect on the current; and x indicates that the peptide has not yet been tested on the current. The responsible authors are mentioned in the introduction as the currents are introduced. The numbers above 
the currents indicate the references from which the information was obtained. (1) Boyd & Walker, 1985, 1987; Cottrell, Davies & Green, 1984; Cottrell & Davies, 1987; (2) Colombaioni, Paupardin-Tritsch, Vidal & Gerschenfeld, 1985; (3) Ruben, Johnson & Thompson, 1986; (4) Brezina, Eckert & Erxleben, 1987b; 
(5)Brezina, Eckert & Erxleben, 1987a; (6) Thompson & Ruben, 1988.
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Methods
Dissection of the Cl neurone. The cerebral ganglia of Helix 
aspersa were removed from the animal and pinned out ventral side 
uppermost in a small Perspex bath lined with a Sylgard base. The 
bath was filled with normal HEPES saline (80mM NaCl, 5mM KCl, 5raM 
MgClg, 7mM CaClg, 20mM HEPES, pH 7.5). The connective tissue 
was dissected away with forceps, and with the aid of a dissecting 
microscope. An agar bridge was incorporated into the circuit 
because the ionic compositions of the two salines used in this 
series of experiments were substantially different. The Cl 
neurone, the largest cell visible on this surface of each ganglion, 
has a diameter of 100-200pm and so is easily identified. The 
cell was impaled with a glass electrode filled with IM CsCl and 
having a resistance of 1-2 MSI. The cell was then voltage clamped 
with a Dagan 8100 single electrode clamp system. Recordings were 
made on a Racal store 4DS recorder.
Protocol. The membrane potential was held at -50mV, and 
the bath saline then replaced by Tris barium saline (25mM BaClg, 
75mM TEACl, lOmM KCl, 5mM MgClg, 3mM 4-AP, 5mM TrisHCl, pH 7.5) 
(modified from Plant and Standen, 1981). The current flowing 
through calcium channels was under investigation here and so is 
referred to as the calcium current, though the actual charge 
carrier through the calcium channels was barium. The cell was 
allowed to rest one minute. Voltage steps of 100ms or 1 second )
duration were applied; first a depolarising step and then an 1
equal hyperpolarising step to record the leakage current. When 
the currents were later analysed with a computer program designed 
by Mr. J. Dempster, University of Strathclyde, the leakage 
currents were subtracted from the calcium currents before
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measurements of the currents were made. The cell was depolarised 
to a maximum membrane potential of +10mV; beyond this value it 
became difficult to clamp the cell. The steps were applied at 
15-20 second intervals so that no voltage step was affected by 
the previous step. The bath saline was then displaced by one 
containing the peptide under investigation at the appropriate 
concentration. The steps were repeated, the peptide was washed 
away, and the steps repeated again.
Channel blockers. The barium saline contained no sodium 
so as to prohibit sodium currents. TEACl and 4-AP were added to 
block the delayed and calcium-dependent potassium currents 
(Hermann & Gorman, 1981a,b). The potassium A current was blocked 
by holding the cell at -50mV (this minimises activation) and by 
the presence of 4-AP in the saline (Thompson, 1977). The calcium- 
dependent and voltage sensitive potassium currents were blocked 
by TEACl (Meech & Standen, 1975). Barium is a potassium channel 
blocker in addition to carrying a larger current through calcium 
channels than calcium itself (Akaike, Lee & Brown, 1978; Eckert & 
Lux, 1976). Thus, theoretically, the only current being observed 
was the inward, voltage-dependent calcium current, though barium 
and not calcium was the charge carrier.
Verification that the peptides were acting on the calcium 
current. To test that this was indeed the case, and that the 
observed net decrease in the inward current was not, in fact, due 
to an increase in the outward potassium current (FMRFamide also 
increases the outward potassium conductance in the Cl neurone 
(Cottrell, Davies & Green, 1984)), the currents were observed in 
the presence of lOmM cobalt and 50faM cadmium. These are calcium
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channel blockers (Akaike, Lee & Brown, 1978). The effects of the 
peptides on the currents in the presence of these ions were also 
investigated.
Peptides. pQDPFLRFamide was a gift from Dr. D. Price 
(Whitney Marine Laboratory, University of Florida). FMRFamide 
and FLRFamide were purchased from Cambridge Research 
Biochemicals, YGGFMRFamide from Peninsula Laboratories and the 
salts in the salines from Sigma or BDH.
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Results
FLRFamide and FMRFamide reversibly reduced the inward 
current (Fig. 27). The threshold for this effect was 
approximately 2pM; IpM tetrapeptide was without effect (Fig. 28). 
The maximum decrease was only 30% of the total calcium current 
and the peptide inhibited a constant fraction of the current over 
the range of stepping potentials investigated (Fig. 29).
Addition of cobalt and cadmium to the barium saline reduced the 
inward current to a negligible level and abolished the effect of 
the peptides (Fig. 30). The three current traces evoked by the 
voltage step in the presence of cobalt and cadmium were 
superimposed upon each other indicating that bath application of 
the peptides had no effect on any current remaining under these 
conditions. Thus it seems highly probable that the current being 
investigated was a calcium channel current and that this current 
was reduced in the presence of FMRFamide and FLRFamide.
pQDPFLRFamide and YGGFMRFamide, however, had no consistent 
inhibitory effect on the current (Figs. 31, 32). The decrease 
in the calcium current exhibited no obvious dose-dependency to 
the tetrapeptides over the concentration range 2-60pM (Table 5).
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Figure 27. The reversible decrease of the calcium current by bath application of SOpM FLRFamide. The membrane potential was held at -50mV and stepped to -lOmV for 1 second.
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Figure 28. The lack of effect of IpM FLRFamide on the calcium current. The membrane potential was held at -50mV and stepped to -lOmV for 1 second.
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Figure 29. A plot of the peak calcium current evoked by holding the membrane potential at -50mV and stepping to the indicated potentials for 1 second. When the steps are repeated in the presence of 8pM FLRFamide the peak current is reduced but the shape of the curve remains constant.
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Figure 30. The calcium current was first evoked in the normal barium saline by holding the membrane potential at -50mV and stepping to -lOmV for 1 second and was reversibly reduced by the presence of 30jjM FLRFamide in the bath. Addition of lOmM C0 CI2 and 50mM CdCl reduced the current to a negligible value. FLRFamide was without effect in their presence as well.
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Figure 31. 60pM pQDPFLRFamide did not reduce the calcium current evoked when the membrane potential was clamped at -50mV and stepped to lOmV for 1 second.
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Figure 32. 30pM YGGFMRFamide was without effect on the calcium current evoked by holding the membrane potential at ~50mV and stepping to -lOmV for 100ms.
103
% DECREASE (mean ± S.E.M.)
= -50mV 
Vg = —lOmV
lAiM 2pM 8pM 15pM 30^ iM 60pM
pQDPFLRFamide
NONE
(2)
NONE
(5)
NONE
(3)
YGGFMRFamide
NONE
(4)
NONE
(5)
FLRFamide
NONE
(4)
15.5 ± 2.72 
(4)
19.4 ± 5.3 
(4)
20.0 ± 2.65 
(3)
FMRFamide
NONE
(4)
20.4 ± 2.23 
(4)
19.7 + 3.57 
(3)
19
(2)
16.3 ± 6.7 
(3)
15.5
(2)
number in brackets = number of experiments
Table 5. A summary of the peptides tested and % decrease (mean +/- standard error of the mean) of the calcium current in their presence at the concentrations indicated. The numbers in brackets are the number of experiments in which each peptide concentration was tested. The membrane potential was held at -50mV and stepped to -lOmV for 100ms or 1 second and the peak 
inward current measured.
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Discussion
The ability of the four FMRFamide analogues to decrease the 
voltage-dependent calcium current seems limited. Only the two 
tetrapeptides were able to effect a decrease and that was limited 
to a maximum value of 30%. N-terminal extension of the tetra­
peptides to heptapeptide length diminished their potency to zero. 
A similar effect of extension on the potency of these peptides 
has been observed for their actions on the sodium current. Table 
6 summarises the currents in Helix aspersa neurones which are 
affected by one or more of the five FMRFamide analogues mentioned 
in this chapter and the effects of these analogues upon the 
currents.
gK
slow gKfast
gNa gKy gCa gK.
FMRFamide + + N E 4- 4-FLRFamide + + N E + + - — XFIRFamide + + N E + + - X X
pQDPFLRFamide + 4" 4* N E mm. — N E XYGGFMRFamide + 4- 4- N E - - N E X
Table 6. A revised table including the effects of FMRFamide, FLRFamide, YGGFMRFamide and pQDPFLRFamide on the various ionic currents investigated in neurones of Helix aspersa. The number of + signs indicates the relative potency of the peptide in increasing the current; the number of - signs indicates the relative potency of the peptide in decreasing the current; N E indicates that the peptide has no effect on the current and x indicates that the peptide has not yet been tested on the current,
FMRFamide modulation of a pacemaker neurone may involve a 
calcium current. FMRFamide suppresses the beating pacemaker 
activity of neurone R15 in Aplysia by suppressing a subthreshold 
(low-voltage-activated, LVA) calcium current (Kramer, Levitan, 
Carrow & Levitan, 1988). The membrane is hyperpolarised and the
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spiking frequency is reduced. This LVA calcium current plays an 
essential role in generating the bursting pacemaker oscillation 
and so modulation of the current by FMRFamide inhibits the 
bursting of the cell. FMRFamide acts directly on the R15 
membrane and not indirectly (for example by activating synaptic 
inputs that inhibit bursting in R15) as isolated juvenile R15 
neurones grown in culture respond to FMRFamide in like manner to 
intact adult neurones.
FMRFamide may inhibit transmitter release by reducing a 
calcium current. The current-voltage relationship of the Cl 
calcium current in Helix resembles that of the high-voltage- 
activated (HVA) current in the B5 neurone of Helisoma trivolvis 
(Haydon & Man-Son-Hing, 1988). The nonsecretory regions of the 
B5 neurone exhibit both LVA and HVA calcium currents. However, 
only the HVA current is present in regions which exhibit secretion. 
The absence of the LVA current may help to ensure that an action 
potential is the only stimulus responsible for transmitter release. 
More recent work on this same system (Haydon, Lukowiak & 
Man-Son-Hing, 1989) has shown that FMRFamide decreases the 
magnitude of the HVA current. As FMRFamide decreases the calcium 
current which is responsible for evoking transmitter release in 
an identified Helisoma neurone in culture, it is likely that it 
may also be acting as a modulator of transmitter release in 
Helix. Thus, if FMRFamide acts at the soma or the terminal of an 
inhibitory neurone in Helix, by depressing release it can cause 
apparent stimulation. Conversely, depressing release of an 
excitatory transmitter would result in apparent inhibition.
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Haydon and Zoran (1989) have provided further evidence for 
this hypothesis. Neurone B5 of Helisoma is a cholinergic neurone 
which will synapse onto the ACh-sensitive neurone B19 in culture.
The release of ACh from B5 can be detected by monitoring the 
electrical activity of B19. Under control conditions a train of 
ten electrically-induced action potentials in B5 evoked an average 
of seven "action potential-evoked postsynaptic potentials" in B19. 
Addition of IpM FMRFamide to the bathing medium reduced this 
number to one and hyperpolarised B5. Washing away the FMRFamide 
restored the number to an average of seven. Thus, FMRFamide did 
appear to reduce the quantity of ACh released from the presynaptic 
terminal.
FMRFamide also affects the secretory apparatus of this system 
(Man-Son-Hing, Zoran, Lukowiak & Haydon, 1989). The B5 neurone 
was dialysed with the photolabile calcium cage nitr-5 (loaded to 
90% capacity with calcium). Epi-illumination of the cell with ÜV 
light released calcium; the increased level of intracellular free 
calcium evoked release of ACh (measured by monitoring B19 as 
before). Experiments with fura-2 showed that IpM FMRFamide did 
not affect the increased level of free calcium in nitr-5-loaded 
cells. However, 1-lOpM FMRFamide did reduce the calcium-dependent 
ACh release evoked by photolytic release of calcium from nitr-5. 
Thus, FMRFamide reversibly decreased the rate of calcium-dependent 
ACh release under conditions of constant and elevated intracellular 
free calcium levels. So, in addition to decreasing a presynaptic 
calcium current required for transmitter release, FMRFamide also 
seems to reduce the sensitivity of the secretory apparatus to raised 
internal calcium —  a second mechanism for presynaptic inhibition.
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